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3. Abstract 
Multiple potentially harmful stimuli challenge the liver, the chief metabolic and 
detoxifying organ of the human body. Due to its central anatomical location, 
continuous blood flow from the gastrointestinal tract through the hepatic 
sinusoids allows the metabolically active hepatocytes, the non-parenchymal cells 
and the various immune cell populations residing and patrolling in the liver to 
interact with antigens and microbiological components coming from the intestine. 
Cytokines are key mediators within the complex interplay of intrahepatic immune 
cells and hepatocytes, as they can activate effector functions of immune cells as 
well as hepatocytic intracellular signaling pathways controlling cellular 
homeostasis. Kupffer cells and liver-infiltrating monocyte-derived macrophages 
(iMϕ) are controlled by cytokines via cytokine-receptors and are primary sources 
of cytokines such as tumor necrosis factor (TNF). TNF can activate specific 
intracellular pathways in hepatocytes that influence cell fate in different manners, 
e.g. pro-apoptotic signals via the caspase cascade, but also survival pathways, 
namely the nuclear factor (NF)-kappaB pathway. One important cytokine-
receptor on the surface of iMϕ responsible for chemotaxis and activation is the C-
C motif chemokine receptor 2 (CCR2). 
Monocyte chemoattractant protein-1 (MCP-1, CCL2), the primary ligand of 
CCR2, is increased in livers patients with non-alcoholic steatohepatitis (NASH) 
and in murine models of steatohepatitis and fibrosis. It was recently shown that 
monocyte / macrophage infiltration into the liver upon injury is critically regulated 
by CCR2 and functionally important for perpetuating hepatic inflammation and 
fibrogenesis. In this study, I investigated pharmacological inhibition of MCP-1 by 
the L-enantiomeric RNA oligonucleotide mNOX-E36, a so-called ‘Spiegelmer’ 
that binds murine MCP-1 / CCL2 with high affinity and neutralizes its action, in 
two murine models of chronic liver diseases in vivo. Antagonizing MCP-1 by 
mNOX-E36 efficiently inhibited murine monocyte chemotaxis in vitro. Upon 
carbon tetrachloride (CCl4)- or methionine-choline-deficient (MCD) diet-induced 
hepatic injury in vivo, the infiltration of macrophages into the liver was 
significantly decreased in anti-MCP-1 treated mice (by FACS and 
immunohistological staining). In line with the lower level of intrahepatic 
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macrophages, pro-inflammatory cytokines (TNFα, IFNγ, IL-6) were significantly 
reduced intrahepatically. In MCD diet-challenged mice a lower level of fatty liver 
degeneration was detected (oil red O staining, intrahepatic triglyceride 
measurement) in mNOX-E36-treated animals. 
Moreover, there is also increasing evidence that distinct monocyte and 
macrophage subsets exert critical functions in regression from organ fibrosis as 
well. Experimental mouse models of fibrosis regression have identified 
‘restorative’ macrophages as Ly-6C (Gr1) low expressing, monocyte-derived 
cells. I aimed at elucidating molecular pathways balancing pro-inflammatory and 
restorative macrophages during fibrosis regression as well as pharmacologically 
augment beneficial macrophage functionality in fibrosis resolution. I therefore 
employed the above mentioned Spiegelmer-based inhibitor of the chemokine 
MCP-1 / CCL2 mNOX-E36 in the regression phase of the two murine models of 
toxic (CCl4) and metabolic (MCD diet) liver fibrosis. Although inflammation rapidly 
declined after cessation of injury, I observed a transient influx of Ly-6C+ 
infiltrating monocytes (iMΦ), which was blocked by mNOX-E36. By inhibiting the 
early influx of Ly-6C+ iMΦ via the CCL2-inhibitor mNOX-E36, the intra-hepatic 
macrophage equilibration shifted towards the ‘restorative’ Ly-6C- subset of iMΦ. 
Consequently, fibrosis resolution was significantly accelerated upon mNOX-E36 
administration in both models. Blocking transient recruitment of infiltrating Ly-6C+ 
monocytes, but not direct effects of the inhibitor on the remaining macrophages, 
resulted in reduced pro-inflammatory cytokines like tumor necrosis factor-alpha 
(TNFα) in the liver. In conclusion, I demonstrate the successful pharmacological 
intervention using the CCL2-inhibitor mNOX-E36 in two independent 
experimental models of fibrosis and fibrosis-regression from toxic and metabolic 
liver injury. 
 10 
4. Zusammenfassung 
Menschen mit einer nicht-alkoholischen Steatohepatitis (NASH), sowie auch 
Mäuse mit experimenteller Steatohepatitis oder Leberfibrose haben erhöhte 
Blutspiegel des Chemokins “Monocyte chemoattractant Protein-1” (MCP-1, 
CCL2), dem Hauptliganden des Chemokinrezeptors CCR2. In der vorliegenden 
Arbeit konnte ich zeigen, dass die Leberinfiltration mit Monozyten / Makrophagen 
CCL2/CCR2 abhängig reguliert wird und dass die CCL2/CCR2-gesteuerte 
Entzündung funktionell bedeutend ist sowohl für die Entwicklung einer 
Organfibrose als auch für die Parenchymheilung nach Leberschädigung. 
Hierzu untersuchte ich die pharmakologische Hemmung von MCP-1 durch das 
RNA-Aptamer mNOX-E36 in zwei unterschiedlichen murinen Modellen der 
chronischen Leberschädigung (metabolisch durch eine Methionin/Cholin 
defiziente Diät (MCD); toxisch durch die Verabreichung von Tetrachlorkohlenstoff 
(CCl4)). mNOX-E36 ist ein l-enantionmeres RNA-Oligonukleotid, dessen 
spezifische  dreidimensionale Struktur CCL2 (MCP-1) spezifisch und effizient 
bindet und dadurch inhibiert. 
Ich konnte zeigen, dass mNOX-E36 die Migration von murinen Monocyten in 
vitro sowie die Infiltration von Blutmonozyten in geschädigten murinen Leber in 
vivo effektiv hemmt. Auch in Modellen chronischer Leberschädigung (CCl4-
Injektionen und MCD-Diät) war mNOX-E36 in der Lage, die hepatische 
Makrophageninfiltration zu inhibieren. Passend zu geringeren intrahepatischen 
Makrophagen waren signifikant reduzierte Spiegel von inflammatorischen 
Zytokinen (TNFα, IFNγ, IL-6) in geschädigten murinen Lebern messbar. Weiter 
konnte im Modell der MCD-Diät durch die Therapie mit mNOX-E36 eine geringer 
ausgeprägte Steatose erreicht werden. 
Im nächsten Schritt war es in der Leberparenchym-Heilung, der so genannten 
Regression, durch die MCP-1 Inhibition möglich eine Veränderung im Verhältnis 
der Unterformen der infiltrierenden Makrophagen zu Gunsten der antifibrotisch 
wirksamen Makrophagen zu erreichen (sog. Ly-6C niedrig exprimierende 
Makrophagen). Somit konnte durch mNOX-E36 eine raschere Regression der 
induzierten Leberfibrose in Mäusen erreicht werden. 
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Meine Studienergebnisse demonstrieren eine erfolgreiche pharmakologische 
Hemmung der Monozyten-/Makrophageninfiltration in chronisch geschädigte 
Lebern durch die Blockierung von CCL2 (MCP-1) in vivo, sowie eine 
Verbesserung der Fibrose-Regression durch das Verändern des 
intrahepatischen immunologischen Mikroklimas. Die hier gezeigten Möglichkeiten 
in die Leberhomeostase einzugreifender eröffnet interessante neue Ansätze für 
die pharmakologische Therapie chronischer Lebererkrankungen. 
 12 
5. Introduction 
The human liver unites a bandwidth of purposes like metabolic, synthetic and 
detoxifying functions. Its exceptional role for regulating body’s homeostasis is 
challenged by liver diseases, whose incidence is increasing globally and which 
represent an outstanding challenge in health care worldwide. While the main 
causes of liver disease in the Western world are non-alcoholic steatohepatitis 
(NASH), alcohol and chronic hepatitis C infections, chronic hepatitis B and C 
infections are major reasons for liver disease in the Middle East and Asia. 
Despite different origins of liver injury, virtually all liver diseases trigger specific 
inflammatory processes, which eventually promote tissue loss, aberrant wound 
healing resulting in liver fibrosis, cirrhosis as an end-stage and occurrence of 
hepatocellular carcinoma 1.  
 
 
Fig. 1 Intrahepatic cell populations 
The healthy l iver comprises about 60-80% hepatocytes; the other intrahepatic 
cell populations include bil iary epithelial cells (cholangiocytes), l iver sinusoidal 
endothelial cells (LSECs) l ining the l iver sinusoids, Kupffer cells (KC), and 
hepatic stellate cells (HSC) in the Dissé space between hepatocytes and LSECs. 
In addition, many immune cells are found in the l iver, mainly entering from the 
circulation via hepatic arteries and portal vein branches, including neutrophils 
(PMN), monocytes (monos), dendrit ic cells (DCs) and lymphocytes (T, B, NK, 
NKT cells). 
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The activation of inflammatory pathways is not necessarily harmful in all 
circumstances. For instance, the liver has also the unique potential to regenerate 
after tissue loss (a process, which is regulated by inflammatory mediators) and 
plays an important role in the regulating blood glucose or blood lipid levels in 
response to the current demand of the body (e.g., in conditions of inflammation). 
The central function of the liver for homeostasis and inflammatory responses is 
also underscored by its sole anatomical location, allowing continuous blood 
supply not only from the arterial system (hepatic arteries) but also from the 
gastrointestinal tract via the portal vein (Fig. 1). Circulating blood cells, e.g. from 
the innate or adaptive immune system, are passing a network of sinusoids 
allowing contact to a variety of intrahepatic cell populations such as parenchymal 
liver cells (hepatocytes), endothelial cells, liver-resident macrophages (Kupffer 
cells) or lymphocyte (mainly NKT cells) populations, hepatic stellate cells and 
others (Fig. 1) 2. 
Communication between these cell types and the regulation of hepatic functions 
are greatly facilitated by cytokines. Cytokines are small molecular weight 
messengers secreted by one cell to alter the behavior of the cell itself (autocrine 
messenger), a closely related cell (paracrine messenger) or cells in different 
organs (endocrine messenger) 3.  
5.1. Intrahepatic immune cells as producers and targets of 
cytokines 
Besides its various metabolic functions, the liver may be also viewed as a central 
immunological organ of the human body. It receives blood coming from the 
gastrointestinal tract though the portal vain, which is enriched with potential 
antigens and microorganisms. Immune cells in the liver have the potential to 
initiate both: a) innate and adaptive immune responses in the case of infections, 
e.g. in response to lipopolysaccharide (LPS) or bacterial superantigens, or b) 
immunological tolerance in the vast majority of harmless antigens during 
homeostasis 4.  
5.1.1. Innate immunity within the liver 
The liver is especially enriched in macrophages (Kupffer cells), natural killer (NK) 
and natural killer T (NKT) cells. Although it has been long known that Kupffer 
cells can principally originate from bone-marrow-derived monocyte, Kupffer cells 
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have long been considered a rather sessile, tissue-resident and (fairly) radio-
resistant population 5,6. Experimental data have challenged this concept, as 
mouse models revealed that approximately half of the Kupffer cells in a steady 
state liver may originate directly from bone-marrow precursors, indicating a high 
turnover rate of macrophages in liver homeostasis 7. Nevertheless, using 
sophisticated cell tracking techniques in mice, recent experiments revealed that 
the majority of Kupffer cells in homeostasis delineate from local precursors and 
constantly renew themselves dependent on the growth factors GM-CSF and M-
CSF 8. However, in the case of inflammation, blood-derived infiltrating monocytes 
are attracted to the injured liver, activated by certain cytokines and become 
dominant for macrophage actions, as suggested by animal models of chronic 
liver injury and fibrogenesis 9,10. Monocytes consist of at least two major subsets 
with different migratory and functional properties 11-13; their specific roles in liver 
homeostasis, inflammation and regression are the subject of intensive ongoing 
research. 
5.1.2. Natural killer (NK) cells in liver homeostasis 
NK cells represent a population of lymphocytes with potent cytolytic activity 
against virus-infected or tumor cells. Hepatic NK cells are regulated by, for 
example, Kupffer-cell derived cytokines, like IL-12 and IL-18, as well as IL-4 
driven by NKT cells 14. Hepatic NK cells produce large amounts of interferon 
gamma (IFNγ) upon activation (Fig. 2), and modulate T cell responses in the 
liver, promote intracellular changes in endothelial cells as well as hepatocytes 
(mainly via IFNγ) and can even directly promote necroptosis of hepatocytes or 
cell lysis. In chronic inflammatory conditions, e.g. chronic hepatitis B virus 
infection, liver injury is closely linked to NK-mediated IL-8 and IFNα synthesis as 
well as accumulation and activation of NK cells in the liver expressing the 
apoptosis-inducing TNF-related apoptosis ligand (TRAIL) 15. 
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Fig. 2 Selected key interactions between 
innate immune cells and hepatocytes 
Kupffer cells (macrophages), NKT and 
NK cells are abundantly found in the 
l iver. Kupffer cells (KC) can release IL-6 
and TNFa, activating hepatocytic gp130-
dependent STAT signaling cascades and 
TNF-R dependent activation of apoptotic 
caspase and/or anti-apoptotic (pro-
inflammatory) NF-kappaB (NFκB) 
pathways. NKT cells exert their actions via release of TNF, IFNγ or FasL-
mediated apoptosis. NK cells can also release IFNγ and may induce apoptosis 
via TRAIL in the case of hepatocytic TRAIL-R expression. 
 
In humans an increase of CD16- NK cells in blood and CD16+ NK cell subset in 
liver are close associated with liver-disease severity and hepatofibrogenesis 16. 
Furthermore, patients suffering from chronic liver diseases show elevated IL-8 
serum levels, according to raised IL-8 producing NK cell population, which is 
associated with a hepatic macrophage accumulation via the IL-8 receptor CXCR1 
17,18 and may promote profibrogenic responses. 
5.1.3. Macrophages in liver homeostasis 
While Kupffer cells are important for sensing liver injury and initiating 
inflammation, infiltrating liver-macrophages (iMϕ) have the capacity to 
phagocytize and release a broad panel of cytokines, which critically determine 
the subsequent reactions of other immune cells and hepatocytes as well as the 
degree of fibrosis by activating myofibroblasts 19. Depending on their 
differentiation (classically activated Ly-6C+ vs. alternatively activated Ly-6C-) iMϕ 
release a variety of proinflammatory cytokines such as tumor-necrosis factor 
(TNF), IL-6, IL-1β or leukotrienes (Ly-6C+ iMϕ) (Fig. 2) 3; or in the context of low 
“physiological” levels of LPS or during liver damage regression, also anti-
inflammatory cytokines like IL-10 and MMP9/12/13 (Ly-6C- iMϕ) 20,21. In acute or 
chronic liver diseases, Kupffer cells and infiltrating monocyte-derived 
macrophages are known to promote inflammatory cascades by releasing these 
proinflammatory mediators with consequences for T cell attraction, NKT cell 
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activation, induction of hepatocyte apoptosis (Fig. 2) or activation of fibrogenic 
hepatic stellate cells (HSC) 14,19,22. 
Chemokines, on the other hand, critically control the infiltration of macrophages 
upon liver injury and thereby promote hepatic inflammation and fibrosis. 
Chemokine receptors like the C-C motif chemokine receptor 2 (CCR2) and CCR8 
can affect trafficking of monocytes/macrophages, DCs and T-helper cells into the 
liver and are critical for inducing liver-fibrosis as well as regeneration depending 
on the time point of secretion and the stage of liver disease 17,21,23,24. Murine 
models revealed that early inflammatory Ly-6C+ iMϕ infiltrate the acute injured 
liver, dependent on chemotaxis through chemokine – receptor interactions CCL2 
- CCR2 or CCL1 - CCR8 23,25-27. After infiltration, these Ly-6C+ iMϕ activate HSC 
and favor their transdifferentiation to myofibroblasts, which leads to enhanced 
collagen production and scar formation 21,28. 
As mentioned above, alternatively activated Ly-6C- iMϕ appear to constitute key 
players in regeneration of liver fibrosis and liver injury regression. Recent studies 
showed that these matured macrophages reduced liver scarring by attracting 
anti-fibrotic and collagen-degrading immune cells resulting into enhanced levels 
of antifibrotic IL-10 and increased metalloproteinases MMP-9 and -13 activation 
10,29,30. Furthermore, recent murine investigations showed significant enhanced 
liver regeneration from fibrosis by pharmacological augmenting the number of Ly-
6C- iMϕ during wound healing 29. 
5.1.4. NKT cells in liver homeostasis 
NKT cells are a heterogeneous population of unconventional T cells that express 
markers of NK cells and T cell receptors (TCRs). NKT cells are found at 
remarkably high numbers in the liver. From studies of experimental liver injury in 
mice after administration of the plant-derived lectin Concanavalin A (ConA), NKT 
cells have been identified as critical factors promoting acute liver damage by 
release of IL-4, IFNγ and direct induction of Fas-mediated hepatocyte apoptosis 
(Fig. 2) 31. NKT subsets with different functions exist in humans and mice: 
classical (type I) invariant (iNKT), other CD1d-dependent (type II) NKT cells, as 
well as CD1d-independent (NKT-like) T cells 14. However, the physiological 
function of the individual subsets is basis of current investigations. Recent 
studies revealed an important role of NKT cells in the development of liver 
fibrosis in mice by accentuating the inflammatory process and activating pro-
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fibrogenic macrophages through the release of cytokines 14,32,33. Furthermore, 
NKT cells are involved in antiviral defense mechanisms by secreting IFNγ, e.g. 
during chronic hepatitis B virus infection as suggested by studies in transgenic 
mice 34.  
5.1.5. Antigen presenting cells and adaptive immune cells in the 
liver 
For the initiation of adaptive immune responses, antigens need to be processed 
and professionally presented to T cells, either in the liver itself or in the draining 
lymph nodes 2. Several hepatic cell populations have antigen-presenting 
properties. In non-inflammatory conditions, antigen-presentation by liver 
sinusoidal endothelial cells appears to be a crucial mechanism for the 
maintenance of immunological tolerance 35. Furthermore, Kupffer cells and also 
bone-marrow derived dendritic cells, mostly of monocytic origin linking the innate 
and adaptive part of immune responses, can efficiently prime T cells 2,19,36. The 
nature of the T cell response, e.g. T-cell cytotoxicity in the case of a chronic viral 
infection or T-cell tolerance in the case of harmless gut-derived antigens or 
autoantigens, seems to depend on the antigen-presenting cells, the cytokine 
milieu and the site of primary T cell activation 37,38. HSCs, known for vitamin A 
storage and collagen synthesis in liver-fibrosis (as activated myofibroblasts), 
have been suggested as cells with antigen-presenting capacity itself that can 
activate T cell responses, e.g. after bacterial challenge 39. 
The liver is also one of the richest sources of γδ T-cells in the body, which are an 
unconventional (or innate) T-cell subset that expresses the γδ TCR. These IL-17 
and IL-22 expressing γδ T-cells are recruited to the liver via chemokine-
chemokine receptor activation (CCL20-CCR6) upon chronic injury and were 
shown to protect the liver from excessive inflammation and fibrosis by inhibiting 
HSC (Fig. 3) 23,40. 
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Fig. 3 Macrophage subsets in 
chronic liver injury 
In the acute phase of hepatic 
injury increased levels of CCL2 
and CCL1 activates ‘classical’ 
Ly-6Chi monocytes via their 
receptors that enter the l iver, 
where they develop into 
infi l trating Ly-6Chi macrophages 
exhibit ing a pro-inflammatory 
phenotype, which partly 
resembles M1 macrophages. 
These macrophages support the 
progression of chronic l iver injury and fibrosis through TGF-β /PDGF-mediated 
HSC transdifferentiation, activation and proliferation. This leads to the 
accumulation of collagen resulting in fibrosis of the organ. After maturation from 
Ly-6Chi to Ly-6Clo macrophages, these cells can adopt a restorative phenotype 
characterized by Ly-6Clo expression and capacity to degrade excessive 
extracellular matrix proteins via metalloproteinases (MMP-9,-12) and to induce 
HSC apoptosis during fibrosis resolution. 
 
5.2. TNF and the TNF-receptor in the liver 
Besides direct effects of immune cells on hepatocytes and other liver cells, 
inflammatory processes in the liver are largely regulated by cytokines. Cytokine 
action is generally mediated by the interaction of cellular receptors with their 
ligand. These networks have evolved early in the evolution; pathways with strong 
homology to human cytokine networks are already found in Drosophila 41.  E.g. in 
Drosophila, Nuclear Factor (NF)-kappaB-like transcription factors are activated in 
order to combat infections; this still represents one major role of cytokine 
networks in higher organisms like humans. Maintaining the ordered balance 
between proliferation and controlled cell death (apoptosis) during embryonic 
development and organogenesis is another important function of cytokines in 
physiologic conditions. The stability of the cytokine relation to each other is 
essential for stable conditions of immune cell response within an organ 3. 
Dysregulated cytokine actions after liver injury, for example, can result in 
excessive apoptosis, a key finding in various acute and chronic liver diseases, 
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e.g. viral and autoimmune hepatitis, cholestatic disease, alcoholic or drug/toxin-
induced liver injury 42. Among the manifold cytokines relevant for liver 
homeostasis and injury, I will highlight important findings on TNF as a represent 
pathway with exceptional significance in the liver. Studies in patients and animal 
models have strongly implicated that death receptor ligands such as TNF or Fas 
ligand (FasL) are involved in the induction of apoptosis / necroptosis and in 
triggering destruction of the liver 43, which leads to final organ failure like liver-
fibrosis. 
TNF and FasL belongs to a family of nine ligands (TNF, lymphotoxin-α, TNFβ, 
FasL, OX40L, CD40L, CD27L, CD30L, 4-1BBL and lymphotoxin-β) that activate 
structurally related receptor proteins known as the TNF receptor superfamily. 
Currently, twelve different death receptors are well established including TNF 
receptor 1 (TNF-R1,Fig. 4), TNF-R2, TNF-RP, Fas, OX-40, 4-1BB, CD40, CD30, 
CD27, pox virus PV-T2, PV-A53R gene products, and the p75 NGFR. In addition, 
the apoptosis-signaling receptors death receptor 3 (DR3), DR4 and DR5, their 
ligand TRAIL, and a nonsignaling decoy receptor TRID/DcR are recently 
identified members of these superfamilies 4,44. In patients with fulminant hepatic 
failure, serum levels of TNF, TNF-R1 and TNF-R2 are markedly increased and 
these changes directly correlated with disease activity. However, in liver 
physiology the TNF-R1 plays a predominant role 43,45. 
5.3. The intracellular TNF pathway controls liver homeostasis 
and inflammation 
In many instances, hepatic failure might result from an imbalance between 
damaging and protective signals that are very tightly regulated under physiologic 
conditions. As mentioned above, TNF and related cytokines are key players in 
liver homeostasis as they can activate both, pro-apoptotic (mainly caspases) and 
anti-apoptotic (mainly NF-kappaB) pathways in hepatocytes (Fig. 4)46-49. 
5.3.1. Activation of pro-apoptotic signaling cascades 
FasL and TNF facilitate programmed cell death in a similar manner by activation 
of caspases. The most important target of both pathways orchestrating cellular 
death is the aspartate-specific cysteine protease- or caspase-cascade, consisting 
of initiator caspases such as caspases 8 and 9 and executioner caspases, e.g. 
caspase 3, 6 and 7. Since proteolytic cleavage generates the mature caspases, 
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one way by which these enzymes are activated is via the action of proteases, 
including other caspases 50. TNF signals through two distinct cell surface 
receptors, TNF-R1 and TNF-R2, of which TNF-R1 initiates the majority of TNF’s 
biological activities. Binding of TNF to its receptor leads to the recruitment of the 
inhibitory protein silencer of death domains (SODD) from TNF-R1’s intracellular 
domain. This results in the activation of the adaptor protein TNF receptor 
associated death domain (TRADD), the central molecule of the TNF signaling, 
which in turn recruits Fas-associated death domain (FADD). FADD recruits 
caspase-8 to the TNF-R1 complex, where it becomes activated and initiates the 
protease cascade leading to activation of executioner caspases and apoptosis 
(Fig. 4) 51-53. 
In hepatocytes, caspase-8-mediated signals are also influenced by a 
mitochondrial pathway: The cytosolic protein Bid (BH3- interacting domain death 
agonist) is proteolytically activated by caspase-8 and thereby converted into its 
active form tBID which translocates into the mitochondrial membrane and 
contributes to increased mitochondrial permeability and subsequent to release 
cytochrome C from the mitochondria into the cytosol via the membrane proteins 
Bax and Bac. The release of cytochrome C triggers the activation of caspase-3 
via caspase-9. Via positive feedback loops, caspase-3 may then activate further 
procaspase-8 molecules, but also directly triggers necroptosis 54-57. Interestingly, 
caspase-8 has two faces within liver homeostasis: mice with hepatocellular 
deletion of caspase-8 were protected against liver injury and 
hepatocarcinogenesis, while caspase-8-deficient immune cells were responsible 
for increased liver injury in models of cholestatic hepatitis 54,58. 
In contrast to TNF-dependent signaling, FasL can interact directly with the death 
domain of FADD without recruiting TRADD 51,55. 
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Fig. 4 TNF signaling in the 
liver 
TNF- binds to its receptors, 
e.g. TNF-R1, and can thereby 
activate the proapoptotic 
caspase cascades (via 
TRADD, FADD and cleavage 
of pro-caspase 8) or the anti-
apoptotic NF-kappaB 
pathway (via activation of the 
IKK-complex resulting in 
phosphorylation of IkBα , 
subsequent translocation of 
NF-kappaB to the nucleus 
and expression of NF-kappaB 
responsive genes). For 
details, please see main text. 
 
 
5.3.2. Activation of the NF-kappaB pathway 
Binding of TNF to its receptor also leads beside of the activation of caspases to 
the activation of the NF-kappaB pathway (Fig. 4). NF-kappaB is a heterodimer or 
a homodimer of members of the Rel family of DNA-binding proteins, and 
regulates the transcription of genes that contain kappaB binding sites. The 
mammalian NF-kappaB family includes five cellular DNA-binding subunits: p50 
(NF-κB1), p52 (NF-κB2), c-Rel (Rel), p65 (RelA) and RelB 59. The  N-terminal Rel 
homology domain (RHD), which is shared by NF-kappaB DNA-binding subunits, 
is responsible for DNA-binding, dimerization, nuclear translocation and 
interaction with the inhibitory I-kappaB proteins. In addition, p65, RelB and cRel 
contain a C-terminal transactivation domain, which activates transcription 46. NF-
kappaB leads to different gene transcription with kappaB binding sites within the 
liver, which are involved in the regulation of inflammation, cell survival and 
immune response 60. 
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In the liver, NF-kappaB mediates protective and anti-apoptotic effects. Thus, 
hepatocytes with a specific deletion for the adapter molecule NEMO that 
abrogates NF-kappaB activation, are hypersensitive for massive TNF-induced 
apoptosis in vivo and in vitro 61. 
TNF-induced activation of NF-kappaB relies on the phosphorylation of two 
conserved serines (S32 and S36 in human I-kappaBα) in the N-terminal 
regulatory domain of I-kappaBs. After phosphorylation, the I-kappaBs undergo a 
second post-translational modification: polyubiquitination by a cascade of 
enzymatic reactions, followed by the degradation of IκB proteins by the 
proteasome, thus releasing NF-kappaB from its inhibitory I-kappaB-binding 
partner, so it can translocate to the nucleus and activate transcription of NF-
kappaB dependent target genes (Fig. 4) 61-63. Since the enzymes that catalyze 
the ubiquitination of I-kappaB are constitutively active, the only regulated step in 
NF-kappaB activation appears to be in most cases the phosphorylation of I-
kappaB molecules. 
A so called “IKK-complex” of high-molecular-weight, that mediates the 
phosphorylation of I-κB has been purified and characterized (Fig. 4). This 
complex consists of three tightly associated I-κB kinase (IKK) polypeptides: IKK1 
(also called IKKα) and IKK2 (IKKβ), the catalytic subunits of the kinase complex 
64-66, and a regulatory subunit called NEMO (NF-kappaB Essential Modulator, 
IKKγ) 49,65. In vitro, IKK1 and IKK2 can form homo- and heterodimers 67. Both 
IKK1 and IKK2 are able to phosphorylate I-κB in vitro, but IKK2 has a higher 
kinase activity in vitro compared with IKK1 65,68-71. 
Activation of the IKK complex upon TNF stimulation involves IKK recruitment to 
the TNF-R1 72-74. Besides TNF-R1, this process involves TNF-receptor-
associated-factor 2 (TRAF2) and the death-domain kinase receptor-interacting 
protein (RIP). After TNF treatment, TRAF2 recruits the IKK-complex to TNF-R1 
via the interaction of the RING-finger motifs of TRAF2 with the leucin-zipper motif 
of both IKK1 and IKK2 72,73. 
In addition, association of TRADD with TRAF2 can activate the Jun-(N)-terminal 
kinases (JNK1/2) via the N-terminal zinc-finger domain of TRAF2. It has been 
demonstrated that activation of the upstream kinases ASK1 (apoptosis signal-
related kinase) and the mitogen-activated kinases MKK4 and MKK7 are essential 
for TNF-mediated JNK1/2 activation 54, which phosphorylates and activates 
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transcriptional factor c-Jun and so regulates the expression of interleukins IL-2 
and IL-8 75. As a possible result IL-2 and its soluble IL-2 recepor is an immune 
cell activator in chronic liver diseases in humans by attracting non-classical 
CD14+ and CD16+ monocytes. 
Recent studies highlighted new potential molecules for drug targeting related to 
NF-kappaB signaling. The molecule receptor interacting protein 3 (RIP3) 
interacts with inflammatory pathways in hepatocytes, because it limits pro-
inflammatory immune response by inhibiting caspase-8-dependent activation of 
JNK1/2 76. RIPs can also directly interact with NEMO and mediate IKK activation, 
although the enzymatic activity of RIP is not required for this process 74,77,78. The 
mechanism by which recruitment of the IKK-complex to the TNF receptor leads to 
IKK activation is not clear, but might involve NEMO induced autophosphorylation 
of the IKK-complex. Moreover, ubiquitination of multiple factors that regulate the 
IKK-complex, like TRAF6/TAK1 or c-IAP1, an inhibitor of apoptosis that is also 
part of the TNF receptor complex, modulate the activity of the NF-kappaB 
pathway 63. 
Nemo and IKKs themselves have also NF-kappaB-independent functions, which 
seem to play a role in the regulation of cell death, carcinogenesis and 
inflammation 79. 
5.3.3. Consequences of NF-kappaB activation in the liver 
After cytokine-consolidation with a death receptor additional to the resulting 
apoptosis of the cell (e.g. liver cell) simultaneously survival signals are activated. 
In the case of the TNF-R this is provided by NF-kappaB. This process is 
assumed to involve the transcriptional induction of various apoptotic suppressors 
80. Evidence that NF-kappaB governs critical anti-apoptotic proteins comes from 
well-described animal models. Injection of TNF into mice and addition of TNF to 
hepatic cells in culture resulted in activation of nuclear translocation and of DNA 
binding of NF-kappaB 81. Moreover, hepatocytes are resistant to apoptosis 
induced by TNF or LPS, a potent inductor for endogenous TNF in the liver, 
unless they are treated with inhibitors of transcription of (anti-apoptotic) proteins 
like cycloheximide or actinomycin D 82-84. Knockout mice lacking the p65 subunit 
of NF-kappaB die between days E15 and E16 post-coitum as a result of fetal 
hepatocyte apoptosis 85. This is caused by increased sensitivity towards TNF, 
since TNF/p65 double-deficient mice are rescued from embryonic lethality 86. 
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Interestingly, IKK subunits in TNF-mediated liver apoptosis have also differential 
functions. Genetic experiments have highlighted that mice lacking IKK1 die 
shortly after birth and display a phenotype marked by thickening of skin and limb 
as well as skeletal defects 87,88. IKK2-deficient mice die in utero approximately at 
embryonic day 12.5 as a result of massive apoptosis in the liver, and fibroblasts 
from these mice show no activation of NF-kappaB in response to TNF 89-91. 
However, deletion of IKK/NEMO causes spontaneous progression of TNF-
mediated chronic hepatitis to HCC, while this deletion of IKK/NEMO in TNFR1 
knockout mice decreased apoptotic cell death, liver-fibrosis and infiltration of 
immune cells 52,92,93. Therefore, at least during embryogenesis, IKK2 and NEMO 
appear to be the critical subunits for NF-kappaB activation and protection of liver 
cells from proinflammatory cytokines like TNF. 
IKK subunits in the adult animal and its role durung TNFR1 activation is less well 
understood. Conditional knockout mice based on the cre/loxP system have 
emerged as new powerful tools to study gene functions in the adult animal in vivo 
41,94. It was shown that hepatocyte-specific ablation of IKK2 does not lead to a 
strongly impaired activation of NF-kappaB or increased apoptosis after TNF 
stimulation, probably because IKK1 homodimers can take over this function in 
the absence of IKK2 in the adult mouse 95. In contrast, conditional hepatocyte-
specific knockout of NEMO resulted in complete block of NF-kappaB activation 
and massive hepatocyte apoptosis, underlining that NEMO is the only 
irreplaceable IKK subunit for prevention of TNF mediated liver apoptosis 61.  
Furthermore, TNF mediated activation of NF-kappaB seems to have besides its 
anti-apoptotic function also critically involvements in various models of 
experimental liver injury. For instance, NF-kappaB DNA-binding occurs quickly 
upon hepatic ischemia-reperfusion (I/R) injury 96, but it has also long been 
unclear whether NF-kappaB dependent signaling withholds a protective or 
damaging role in I/R injury. It was shown that hepatocyte-specific conditional 
knockout mice for IKK2 show a defect in NF-kappaB activation after I/R 95. 
Inhibition of NF-kappaB activation in conditional IKK2-deficient mice protected 
from liver injury due to I/R 95, thus underlining that, depending on the 
experimental model, the NF-kappaB pathway does not serve as a survival 
pathway, but instead can aggravate hepatocyte death and liver damage. 
However, complete abolishment of NF-kappaB activation in conditional NEMO-
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knockout mice resulted in massive hepatic inflammation and apoptosis after I/R 
injury 61. 
5.4. Cytokine dependent injury of the liver 
A growing number of studies have implicated immune cells, cytokines and 
cytokine-dependent pathways in the development of liver failure, chronic liver 
disease, hepatic inflammation and liver fibrogenesis. Resident and infiltrating 
immune cells depending on their differentiation, detectable by their cell-surface 
markers, have been linked to progression (especially Ly-6Chi expressing iMϕ) as 
well as regression of liver injury (e.g., Ly-6Clo iMϕ) 21,29. On the other hand, 
parenchymal and non-parenchymal survival pathways like NF-kappaB withhold a 
protective function in many experimental liver disease models and thus are an 
attractive target for a pharmacological intervention 97. However, many 
experimental models highlighted dual functions of these key players, namely 
beneficial or adverse effects. For instance, blockage of monocyte infiltration into 
the liver limits disease progression in different murine models, but also negatively 
affect the resolution of liver fibrosis 6. Thus, an inflammatory immune cell is not 
necessarily detrimental in any context. Similarly, an inhibition of NF-κB in the liver 
can have different outcomes depending on the experimental model applied: 
protecting from apoptosis in a model of TNF-dependent cell death vs. 
aggravating cellular necrosis in a model of ischemia/reperfusion injury 98. Thus, a 
survival pathway is not necessarily protective in any context. Dissecting the 
cellular and molecular inflammatory pathways during liver homeostasis and 
during liver injury will hopefully provide the basis for novel specific therapeutic 
approaches in the near future. 
5.4.1. Cytokine dependent steatosis and steatohepatitis of the 
liver 
Albeit the underlying cause of chronic liver disease can be as a different as 
metabolic disorders, viral hepatitis, alcohol abuse, autoimmunity or others, 
chronic liver injury leads to a characteristic remodelling of the organ: fibrosis of 
the liver and hepatocytic accumulation of fat (steatosis) 1. Hepatic steatosis is 
also commonly observed in systemic metabolic diseases like diabetes, obesity 
and dyslipidemia, often progressing to non-alcoholic steatohepatitis (NASH), with 
evidence of both: hepatocellular injury and chronic inflammation with infiltration 
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by leukocytes 99. The inflammatory reaction in the liver has been clearly shown to 
be critical for the development and aggravation of steatosis as well as for 
induction and progression of organ fibrosis 1,100,101. On a cellular level, the 
activation of liver-resident macrophages, traditionally called ‘Kupffer cells’, and 
the vast infiltration of monocytes into the injured liver have been identified as 
major pathogenic factors, because this pool of hepatic macrophages releases 
essential pro-inflammatory cytokines (e.g., TNF) promoting hepatocellular stress 
responses and lipid accumulation 9,26,102. Moreover, hepatic macrophages also 
produce profibrogenic (e.g., TGF-β) mediators and can directly activate collagen-
producing hepatic stellate cells (HSC), thus linking inflammation to aberrant 
wound healing in the liver 26,28,102. 
5.4.2. CCR2 expressed by liver macrophages 
On a molecular level, compelling evidence exists that macrophage infiltration into 
the liver is primarily driven by C-C chemokine receptor 2 (CCR2) and its main 
ligand CCL2, monocyte chemoattractant protein-1 (MCP-1), in mice and men 
10,26,102-104. In the injured liver, MCP-1 is synthesized by activated stellate cells, 
hepatocytes, macrophages and endothelial cells 28,101,103, thereby representing a 
central and redundantly activated pathway for liver inflammation. Functionally, 
CCR2-deficient or MCP-1-deficient mice were shown to be protected from liver 
fibrosis in experimental models 26,103-105. In humans, increased hepatic MCP-1 
expression levels as well as CCR2-dependent macrophage infiltration have been 
confirmed in patients with fibrosis and cirrhosis 102,106,107. Of note, MCP-1 
appears to be particularly up-regulated in patients with NASH, both 
intrahepatically and systemically 108. 
In this study, I set out experiments to test whether pharmacological inhibition of 
hepatic macrophage infiltration via blocking MCP-1 ameliorates liver damage, 
steatosis and fibrosis in experimental models. In our work, I employed for the first 
time an MCP-1 specific ‘Spiegelmer’ in models of murine liver injury.  
5.4.3. The MCP-1 specific ‘Spiegelmer’ mNOX-E36 
Spiegelmers have been developed on the basis that biological effects of 
cytokines or other endocrine molecules can be specifically neutralized by l-
enantionmeric RNA molecules (aptamers) 109. Unfortunately, the therapeutic use 
of traditional aptamers is limited by their susceptibility to ubiquitous nucleases. 
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Unlike aptamers, the Spiegelmers are modified oligonucleotides that are 
nuclease-resistant thus biostable and immunologically inert 110. Moreover, by 
polyethylene glycol (PEG) modification Spiegelmers have a relatively long half-
life in plasma, allowing even long-term therapeutic approaches 110. Thus, the 
Spiegelmer technology is an elegant solution to synthesize biostable inhibitors as 
l-enantionmeric RNA or DNA, which are able to bind and block their target 
molecule comparable to an antibody. The Spiegelmer mNOX-E36 binds with high 
affinity to murine MCP-1 and inhibits its biological effects already at low 
nanomolar concentrations 111. In pilot studies, mNOX-E36 has been successfully 
tested as a therapeutic agent against macrophage-mediated diabetic 
nephrosclerosis in rodents, and its human equivalent is currently being used in a 
phase Ib clinic trial on humans with diabetes targeting their diabetic nephropathy 
(ClinicalTrials.gov number NCT01085292). In order to unravel the therapeutic 
potential of MCP-1 inhibition in chronic liver diseases and liver injury regression, I 
investigated the effects of specific pharmacological MCP-1 inhibitor mNOX-E36 
in two experimental models on the development of toxic (CCl4) and metabolic 
(MCD diet) liver injury in mice.  
5.4.4. Macrophages in liver fibrosis regression 
Liver fibrosis is a characteristic consequence of chronic organ inflammation. 
Persistent hepatic inflammation promotes apoptosis of parenchymal cells and 
replacement by connective tissue and extracellular matrix (ECM) proteins. 
However, the traditional view of liver fibrosis as an irreversible process is 
obsolete, because it is now evident that the development of hepatic fibrosis is a 
dynamic and potentially bidirectional process. Spontaneous resolution of scarring 
is seen in animal models of liver fibrosis and in human trials in which the stimuli 
responsible for chronic or repeated hepatic inflammation is successfully removed 
112,113.  
Inflammatory monocytes and activated macrophages in injured liver release pro-
inflammatory and pro-fibrogenic cytokines, orchestrate the subsequent 
inflammatory reaction and directly activate hepatic stellate cells (HSC), the main 
collagen-producing cell in the liver, in murine models of liver fibrosis as well as in 
human fibrotic liver  26,114,115. However, macrophages appear to be important 
beneficial contributors to fibrosis regression as well. The selective depletion of 
macrophages, using a transgenic mouse model with diphtheria toxin receptor 
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expression on myeloid (CD11b+) cells, during the resolution phase after 
experimental injury significantly impaired resolution of fibrosis 6. Moreover, 
macrophage derived elastase MMP-12 regulates the degradation of elastin, 
which is a major ECM component characterizing advanced fibrosis/cirrhosis 112. 
In line, the adoptive transfer of macrophage subsets into (regressing) 
experimental fibrosis was shown to improve hepatic fibrosis in mice as well as 
the adoptive transfer of myeloid (likely monocyte-derived) dendritic cells 116.  
These data collectively indicated the presence of ‘restorative macrophages’ 
during fibrosis regression, which likely derive from an infiltrating monocyte 
precursor. By using sophisticated labelling, transfer and depletion strategies in 
mice, macrophages with a clear restorative phenotype were recently identified as 
a low Ly-6C expressing subpopulation (Ly-6C-) of infiltrating macrophages (iMΦ) 
in regression from murine toxic liver fibrosis 117. During scar remodelling, the 
subsets of iMΦ can undergo a shift from rather immature Ly-6C+ to more mature 
Ly-6C- macrophages118. 
5.4.5. MCP-1 inhibition during liver fibrosis regression 
It is currently unclear, by which pathways these ‘restorative macrophages’ are 
recruited or regulated or whether augmentation of such beneficial macrophage 
subsets could be achieved by pharmacological interventions. Because the 
chemokine receptor CCR2 was found to be mainly responsible for the 
recruitment of pro-inflammatory and pro-fibrogenic infiltrating monocytes during 
fibrosis progression 26, I hypothesized that pharmacological inhibition of the 
chemokine CCL2, also called monocyte chemoattractant protein 1 (MCP-1), 
might bear therapeutic potential during fibrosis regression. In the injured liver, 
MCP-1 is synthesised by activated stellate cells, hepatocytes, macrophages and 
endothelial cells 103,119. In patients with fibrosis and cirrhosis, increased hepatic 
MCP-1 expression levels as well as CCR2-dependent macrophage infiltration 
have been described 102,106. CCR2- or MCP-1-deficient mice were shown to be 
protected from liver fibrosis in experimental models 25,26,103, but displayed also 
altered kinetics of regression from injury 104. 
In order to test our hypothesis, I used the obove-mentioned MCP-1 inhibiting 
‘Spiegelmer’. The Spiegelmer employed in our studies, mNOX-E36, binds with 
high affinity to murine MCP-1 and inhibits its biological effects at low nanomolar 
concentrations.  
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6. Materials & Methods 
6.1. Spiegelmers 
The Spiegelmer mNOX-E36 (40-nucleotide L-RNA oligonucleotide; 5’-
GGCGACAUUGGUUGGGCAUGAGGCGAGGCCCUU-UGAUGAAUCCGCGGC 
CA-3’) was kindly provided by Noxxon Pharma AG (Berlin, Germany). It binds 
specifically to murine MCP-1 (CCL2) and inhibits the biological effects of MCP-1 
in vitro at low nanomolar concentrations 111,120. Rev-mNOX-E36, consisting of the 
reverse nucleotide sequence, served a non-functional control Spiegelmer. Both 
drugs were terminally modified with 40-kDa polyethylene glycol (PEG) and 
injected subcutaneously three times per week at a dose of 20mg/kg body-weight 
111,120.  
6.2. Migration assay 
Total bone marrow was isolated from untreated mice and subjected to red cell 
lysis using Pharmlyse (BD). Migration assays towards CCL2 (eBioscience, 
100ng/ml) were performed in the presence or absence of mNOX-E36 through a 
semipermeable migration membrane (pore size 5µm, Millipore) under sterile cell 
culture conditions in IMDM Medium (Debecco). The migrated population was 
analysed by fluorescence activated cell sorting (FACS). 
6.3. Mice 
C57BL/6 Wildtype (WT) and CCR2-/- mice (backcrossed to C57BL/6 background 
for more than eight generations) were maintained in our colony. All mice were 
housed in a pathogen-free environment. All experiments were performed with 
male animals at 6 to 8 weeks of age under ethical conditions approved by the 
appropriate authorities according to German legal requirements. 
6.4. Induction chronic liver injury 
For induction of toxic liver fibrosis, carbon tetrachloride (CCl4, Merck) mixed with 
corn oil was injected at a dose of 0.6 ml/kg body weight twice weekly for 6 weeks. 
As controls, animals received the same volume of the tracer (corn oil) 
intraperitoneally. Mice were sacrificed at the indicated time-points. For induction 
 30 
of steatohepatitis and fibrosis, mice were fed a methionine-choline-deficient 
(MCD) diet for 8 weeks (MP Biomedicals, Cat.No. 390439) and sacrificed at the 
indicated time-points 21,26. For regression studies, injections of CCl4 were 
discontinued or mice were switched from a MCD to a normal chow diet. 
6.5. Analysis of blood, bone marrow and intrahepatic 
leukocytes 
Whole blood was drawn from heart puncture, and bone marrow was isolated from 
excised femurs. Cells were subjected to red cell lysis using Pharmlyse (BD), 
washed twice with DMEM containing 5mM EDTA and 0.5% BSA and then 
stained with antibodies. For flow-cytometric analysis of intrahepatic leukocytes, 
livers were perfused with 20 to 40ml PBS, minced with scissors and 
subsequently digested for 30 minutes with collagenase type-IV (Worthington) at 
37°C. Digested extracts were pressed through 70 µm cell strainers to gain single 
cell suspensions. A small aliquot was stained with CD45 to assess the relative 
amount of intrahepatic leukocytes (CD45+) among all liver cells. The remaining 
liver single cell suspension was subjected to density gradient centrifugation 
(LSM-1077, PAA) at 2,000 rpm for 20 minutes at 25°C. Leukocytes were 
collected from the interphase after centrifugation, washed twice with Hank’s 
balanced salt solution containing 2% BSA and 0.1mM EDTA, and subjected to 
FACS 26,121. 
6.6. Flow cytometry 
Multi-color FACS staining was conducted using combinations of the following 
monoclonal antibodies: F4/80 (Serotec), CD115, CD4, CD11c, CD11b (all 
eBioscience), CD45, Gr1/Ly6C, Ly6G, CD19, CD25, NK1.1, CD3, CD8 (all BD). 
Dead cells were excluded by Hoechst 33258 dye (Sigma-Aldrich). Analysis was 
performed using a FACS Canto-II (BD), cell sorting by using FACS Aria-II-SORP 
(BD). Data were analysed with FlowJo (TreeStar). 
6.7. Liver enzymes, histology and immunohistochemistry 
Alanine aminotransferase (ALT) activity and aspartate aminotransferase (AST) 
activity (UV test at 37°C) were measured in serum (Roche Modular preanalytics 
system). Conventional hematoxylin-eosin (H&E), Sirius red, and Oil red O 
stainings were performed according to standard protocols 122. Sirius red stained 
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pictures were analysed by area fraction quantification program in a blinded 
fashion (ImageJ). Liver sections from fixed paraffin blocks were 
immunohistochemical stained according to standard procedures using the 
following antibodies: anti-mouse F4/80 (Serotec) and CD45 (BD). Absolute 
counts of CD45+ cells (leukocytes) per high-power field of stained liver sections 
were manually assessed by an experienced pathologist in a blinded fashion. 
6.8. Real-time gene expression analysis 
Livers were harvested and snap frozen in liquid nitrogen. RNA was purified from 
frozen liver samples by pegGOLD (peqLab), and complementary DNA was 
generated from 1µg RNA using a complementary DNA synthesis kit (Roche). 
Quantitative realtime polymerase chain reaction (PCR) was performed using 
SYBR Green Reagent (Invitrogen). Reactions were done twice in triplicate, and 
β-actin values were used to normalize gene expression. Primer sequences are 
available upon request 12. 
6.9. Hydroxyproline, cytokine and triglyceride measurements 
The hepatic hydroxyproline content as a measure for total collagen was 
measured as described 26. Briefly, liver samples were hydrolyzed with 6N HCl at 
110°C for 16 hours, then filtered and mixed with methanol and evaporated by a 
vacuum concentrator (Eppendorf). The crystallized samples were dissolved in 
50% isopropanol and incubated with 0.6% chloramine-T for 10 minutes. Freshly 
prepared Ehrlich’s reagent was added, and samples were incubated at 50°C for 
45 minutes under constant shaking. Samples were measured at 570 nm, and 
concentrations of total liver hydroxyproline were calculated against a standard 
curve. MCP-1, IL-6, IFNγ and TNFα concentrations were measured from protein 
extracts of liver by ELISA (eBiosciences). Protein content was quantified by a 
photometric assay (Biorad). The intrahepatic triglyceride content was measured 
by TG liquicolor mono (Human Diagnostics) according to manufacturer’s 
instructions from homogenized snap-frozen liver samples 21. 
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6.10. Bone marrow-derived macrophages and in vitro 
stimulation 
Bone marrow cells were isolated from femur and tibia of 8 weeks old c57BL6/J 
mice 13. To obtain fibroblast-conditioned medium (FCM), L929 fibroblasts were 
cultured in RPMI medium containing 10% fetal calf serum (FCS) for three days, 
when the cells were still in the growth phase, and the supernatant was collected 
and stored until usage at -80 °C. For the generation of bone marrow-derived 
macrophages (BMM), bone marrow cells were cultured in RPMI medium 
containing 10% FCS and 20% FCM for one week on bacterial grade plastic 
plates. At day 7, cells were either left untreated or incubated with mNOX-E36 
(200 mg/mL). After 24h, cells were either left unstimulated or stimulated for 
additional 24h with recombinant murine interleukin 4 (IL4, 100 ng/mL) or 
recombinant murine gamma interferon (IFNγ, 20 ng/mL, both from PeproTech 
Inc., New Jersey, USA).  
6.11. Statistical analysis 
All data are presented as mean ± standard deviation (SD). Differences between 
groups were assessed by two-tailed unpaired Student’s t-test (GraphPad prism). 
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7. Results 
7.1. mNOX-E36 efficiently inhibits mouse monocyte migration in 
vitro 
Recent studies using CCR2-/- mice demonstrated that chemokine receptor CCR2 
and its ligand MCP-1/CCL2 promote the infiltration of inflammatory Gr1+ (Ly6C+) 
monocytes into the liver 26,103,104. Subsequently, these monocytes were found to 
exert pro-inflammatory along with pro-fibrogenic actions by the release of distinct 
cytokines and direct interactions with hepatic stellate cells. Thus, inhibition of 
hepatic monocyte infiltration via blocking MCP-1 could represent a promising 
therapeutic approach during fibrogenesis. The main mechanism of MCP-1 action 
is likely to promote exit of Gr1+ monocytes from the bone marrow into the blood. 
In order to elucidate the possibility of pharmacological inhibition of monocyte 
migration by the MCP-1 antagonist mNOX-E36, bone marrow cells from C57BL/6 
wild-type (WT) mice were investigated in a chemotaxis experiment. Bone marrow 
cells were allowed to migrate through a semi-permeable membrane with a pore 
size of 5µm upon stimulation with MCP-1, and the fraction of migrated cells was 
analysed by FACS. Simultaneous incubation of cells with the murine MCP-1 
specific RNA Spiegelmer mNOX-E36 efficiently and specifically inhibited the 
MCP-1-dependent migration of bone marrow monocytes (Fig. 5). The inhibition of 
MCP-1 via mNOX-E36 restrained monocyte migration to a similar extent as in 
CCR2-/- cells. Other leukocyte populations were not affected by mNOX-E36 (not 
shown). These experiments prompted us to investigate whether mNOX-E36 was 
able to inhibit hepatic monocyte accumulation in liver injury models in vivo. 
 
Fig. 5 mNOX-E36 inhibits CCL2-
dependent migration of monocytes in 
vitro 
Monocytes were isolated from bone 
marrow of either wildtype (WT) or 
CCR2-deficient (CCR2-/-) mice. 
Migration of monocytes (defined as 
l ive CD11b+ Ly6G- CD45+ cells) 
towards a gradient of 100ng/ml 
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recombinant murine CCL2 (MCP-1) was quantif ied after 4hrs. Migration of 
unstimulated WT monocytes was set to 1. Data are expressed as mean ± SD 
from three independent experiments. *P<0.05 (unpaired Student’s t-test) 21. 
 
7.2. mNOX-E36 specifically inhibits hepatic macrophage 
infiltration in vivo upon acute liver injury 
In order to test the therapeutic potential of blocking MCP-1 for liver disease, 
mNOX-E36 was applied to WT mice that were challenged with a single dose of 
CCl4 i.p. to induce an acute toxic hepatic damage. CCl4 resulted in periportal 
necroses with maximal damage after 48 hours with correspondingly highly 
elevated serum ALT activities and severe accumulation of leukocytes in injured 
livers, as assessed by FACS analysis and immunohistochemistry (not shown) for 
the pan-leukocyte marker CD45. Administration of mNOX-E36 efficiently reduced 
intrahepatic leukocyte infiltration, to a similar level as seen in CCR2-/- mice (Fig. 
6). 
Previous studies revealed that the predominant infiltrating immune cells early 
after liver injury are macrophages 26,121. Therefore, I purified leukocytes from liver 
tissues and characterized the distinct cell types by FACS analysis. Intrahepatic 
macrophages were defined as living (Hoechst-dye negative) CD45+ cells that 
stain positive for the myeloid marker CD11b, positive for the macrophage marker 
F4/80 and negative for the neutrophil marker Ly6G 26. While WT mice showed 
massively increased hepatic macrophages after CCl4 injection, these cells only 
mildly increased in livers of mNOX-E36 treated mice. 
Like CCR2-/- mice, mNOX-E36 treated mice displayed significantly reduced 
macrophage infiltration following acute liver injury. Importantly, other leukocyte 
subpopulations such as T-cells (CD8+, CD4+) or B-cells (CD19+) were not 
affected by mNOX-E36 administration (Fig. 7). 
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Fig. 6 mNOX-E36 specifically inhibits hepatic macrophage infiltration upon acute liver 
injury in vivo 
Acute toxic l iver injury was induced by 0.6ml/kg carbon tetrachloride (CCl4) i.p. 
in c57bl/6 WT mice. 20mg/kg mNOX-E36 was administered s.c. simultaneously. 
Mice were analysed 48h thereafter. (A) Conventional hematoxylin-eosin staining 
of l iver paraffin sections showed necrotic patches and progressive mononuclear 
infi l trates (arrows) in the periportal regions after acute l iver injury. (B) Hepatic 
injury was also assessed by serum ALT levels. (C) Infi l tration of leukocytes into 
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the l iver was quantif ied by FACS (percentage of CD45+ cells from total l iver 
cells), revealing decreased counts in CCR2-/- and mNOX-E36 treated mice. (D) 
FACS analysis of intrahepatic leukocytes, pre-gated on l ive (Hoechst-dye-) 
CD45+ Ly6G- cells, showing reduced numbers of CD11b+F4/80+ intrahepatic 
macrophages after mNOX-E36 injection and in CCR2-/- mice. Left: representative 
FACS plot, r ight: quantitative analysis. (E) FACS analysis of leukocytes from 
peripheral blood analyzing circulating monocytes (defined as CD11b+Ly6G- 
cells). (F) FACS analysis of leukocytes from bone marrow analyzing monocytes 
(defined as CD11b+Ly6G- cells). All data are expressed as the mean ± SD from 
three independent experiments, comprising n=8-10 for animals in the treatment 
and n=5 animals in the control groups. *P<0.05, **P<0.005, ***P<0.001 
(unpaired Student’s t-test) 21. 
 
Besides characterizing the subsets of leukocytes in the liver I also analysed 
corresponding monocyte populations in blood and bone marrow compartments. 
Not only accumulation of monocytes in injured liver, but also monocyte 
emigration out of the bone marrow was found to be inhibited by mNOX-E36. This 
effect was shown by an increased pooling of Ly6G- CD11b+ monocytes in blood 
and bone marrow compared to untreated mice (Fig. 6). Of note, CCR2-/- mice 
also displayed retention of monocytes in the bone marrow, as anticipated from 
prior studies. The pharmacological effects on monocyte migration were specific 
for the RNA Spiegelmer mNOX-E36, because the inert reverse Spiegelmer rev-
mNOX-E36, which is a backwards-synthesized mNOX-E36, did not reveal these 
effects on monocytes (not shown). The clear inhibition of hepatic macrophage 
accumulation upon injury by mNOX-E36 in vivo prompted us to examine its 
application in chronic disease models. 
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Fig. 7 Effects of mNOX-E36 on non-macrophage hepatic leukocyte infiltration upon 
acute liver injury in vivo 
Acute toxic l iver injury was induced by 0.6ml/kg carbon tetrachloride (CCl4) i.p. 
in c57bl/6 WT mice. 20mg/kg mNOX-E36 was administered s.c. simultaneously. 
Mice were analysed 48h thereafter. (A) FACS analysis of intrahepatic 
leukocytes, pre-gated on l ive (Hoechst-dye-) CD45+ Ly6G- cells, showing 
unaffected numbers of CD4+ and CD8+ T cells after mNOX-E36 injection. (B-E) 
Statistical analysis, based on FACS staining for intrahepatic leukocytes, 
revealed no significant alterations of hepatic non-macrophage immune cell 
subpopulations, specifically T-helper cells (CD4+, B), cytotoxic T cells (CD8+, C), 
B cells (CD19+, D) or neutrophils (Ly6G+, E). All data are expressed as the mean 
± SD from three independent experiments, comprising n=8-10 for animals in the 
treatment and n=5 animals in the control groups. *P<0.05, **P<0.005, 
***P<0.001 (unpaired Student’s t-test) 21. 
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7.3. Chronic liver injury 
7.3.1. mNOX-E36 specifically inhibits hepatic macrophage 
infiltration in vivo in two models of chronic liver injury 
The infiltration of macrophages into the liver upon chronic injury has been 
convincingly linked to the progression of liver inflammation and fibrosis in mice 
and men 6,26,102,121. I therefore next investigated the therapeutic effects of mNOX-
E36 in models of chronic damage. Mice were challenged with CCl4 i.p. twice a 
week for six weeks and received simultaneously mNOX-E36 (20 mg/kg) s.c. 
three times a week for this period. CCl4-treated animals displayed a severe toxic 
liver damage with increased serum ALT and AST (Fig.8), necrotic patches in 
histology and mononuclear infiltrates. The massive influx of leukocytes, 
especially macrophages, was visualized by immunohistological staining for CD45 
and F4/80 (Fig. 8). 
 
See over for figure legend 
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Fig. 8 mNOX-E36 specifically inhibits hepatic macrophage infiltration upon chronic 
CCl4-induced toxic injury in vivo 
Chronic toxic l iver injury was induced by 0.6ml/kg CCl4 i.p. twice weekly in 
c57bl/6 WT mice. 20mg/kg mNOX-E36 was administered s.c. three times per 
week. Mice were after 6 weeks of repetit ive CCl4 treatment, 48h past the last 
injection. (A) Hepatic injury was assessed by serum ALT levels. (B) Infi ltration of 
leukocytes into the l iver was quantif ied by immunohistochemistry for the pan-
leukocyte marker CD45. Counts of CD45+ cells were manually counted by a 
blinded pathologist from 10 independent random viewfields per sample, 
revealing reduced intrahepatic leukocytes in mNOX-E36 treated and CCR2-/- 
mice. (C) Representative immunohistochemical stainings for total leukocytes 
(CD45) and macrophages (F4/80) on l iver paraffin sections from different 
experimental conditons. (D) FACS analysis of intrahepatic leukocytes, pre-gated 
on l ive (Hoechst-dye-) CD45+ Ly6G- cells, showing reduced numbers of 
CD11b+F4/80+ intrahepatic macrophages after mNOX-E36 injection and in CCR2-
/- mice. Left: representative FACS plot, r ight: quantitative analysis. (E) FACS 
analysis of leukocytes from peripheral blood analyzing circulating monocytes 
(defined as CD11b+Ly6G- cells). (F) FACS analysis of leukocytes from bone 
marrow analyzing monocytes (defined as CD11b+Ly6G- cells). All data are 
expressed as the mean ± SD from three independent experiments, comprising 
n=10-13 for animals in the treatment and n=5-7 animals in the control groups. 
*P<0.05, **P<0.005, ***P<0.001 (unpaired Student’s t-test) 21.  
 
In line with the effects observed after single administration of CCl4 and mNOX-
E36, long-term treatment of mice with mNOX-E36 attenuated leukocyte influx in 
chronic liver damage, similarly as in CCR2-/- mice. Again, macrophages were the 
predominant leukocyte population in chronic injury as well, and macrophage 
accumulation was strongly reduced in mNOX-E36-treated and in CCR2-/- mice, 
as evidenced by immunohistochemistry and FACS analyses (Fig. 8). The 
unspecific Spiegelmer control (revmNOX-E36) had no effect on intrahepatic 
macrophages in chronic CCl4 treatment (not shown). Parallel to the intrahepatic 
macrophages I investigated other immune cells like T-cells (CD8, CD4+) or NK-
cells (NK1.1+), which were not affected by CCR2-knock-out or mNOX-E36 
treatment (Fig. 9). Besides liver tissue I analysed once more also blood and bone 
marrow by FACS. In blood I detected concordant to the CCR2-/- mice lower levels 
of monocytes in the mNOX-E36 injected mice. CCR2-/- mice, but not mNOX-E36-
treated animals retained monocytes in the bone marrow (Fig. 8). 
 
 40 
Fig. 9 Effects of 
mNOX-E36 on non-
macrophage hepatic 
leukocyte infiltration 
upon chronic CCl4-
induced liver injury 
in vivo 
Chronic toxic l iver 
injury was induced 
by 0.6ml/kg CCl4 
i.p. twice weekly in 
c57bl/6 WT mice. 
20mg/kg mNOX-
E36 was 
administered s.c. three times per week. Mice were after 6 weeks of repetit ive 
CCl4 treatment, 48h past the last injection. (A-D) Statistical analysis, based on 
FACS staining for intrahepatic leukocytes, revealed no significant alterations of 
hepatic non-macrophage immune cell subpopulations, specifically T-helper cells 
(CD4+, A), cytotoxic T cells (CD8+, B), NK cells (NK1.1+CD3-, C) or NKT cells 
(NK1.1+CD4+, D). All data are expressed as the mean ± SD from three 
independent experiments, comprising n=10-13 for animals in the treatment and 
n=5-7 animals in the control groups. *P<0.05, **P<0.005, ***P<0.001 (unpaired 
Student’s t-test) 21. 
 
In order to exclude that these results had been confounded by model-specific 
effects, I employed a second model of liver injury. Mice were fed a methionine 
and choline-deficient (MCD) diet for 8 weeks, resulting in severe steatohepatitis 
at a macroscopic and microscopic level. Mice were severely ill with substantial 
weight loss and elevated ALT and AST (not shown) levels in comparison to mice 
fed a control diet. Liver histology showed a diffuse infiltration with leukocytes, 
apoptotic areas and a massive fatty degeneration. By immunohistochemistry and 
FACS analysis, I found once again decreased numbers of intrahepatic leukocytes 
as well as macrophages in CCR2-/- and mNOX-E36 treated animals upon chronic 
metabolic injury (Fig. 10). Other intrahepatic leukocyte populations were not 
affected in the MCD diet model either (Fig. 11). Similar to the toxic injury model, 
the total numbers of blood monocytes were again decreased for CCR2-/- and 
mNOX-E36 injected mice, while in bone marrow the monocyte population was 
only pooled in CCR2-/- mice (Fig. 10). 
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Fig. 10 mNOX-E36 specifically inhibits hepatic macrophage infiltration upon chronic 
MCD diet-induced metabolic injury in vivo 
C57bl/6 WT mice were fed by a methionine choline deficient (MCD) diet for 8 
weeks. 20mg/kg mNOX-E36 was administered s.c. three times per week. (A) 
Representative macroscopic pictures of the l ivers (scale marks indicate 1cm) 
and corresponding hematoxylin-eosin staining of l iver paraffin sections. (B) 
Change of body weight from baseline after 8 weeks of MCD diet in the different 
treatment groups. (C) Hepatic injury was assessed by serum ALT levels. (D) 
FACS analysis of intrahepatic leukocytes, either presented as total leukocytes 
(defined as l ive CD45+ cells, left) or macrophages (defined as l ive 
CD45+CD11b+F4/80+Ly6G- cells, right). (E) FACS analysis of leukocytes from 
peripheral blood analyzing circulating monocytes (defined as CD11b+Ly6G- 
cells). (F) FACS analysis of leukocytes from bone marrow analyzing monocytes 
(defined as CD11b+Ly6G- cells). All data are expressed as the mean ± SD from 
three independent experiments, comprising n=10-12 for animals in the treatment 
and n=5-7 animals in the control groups. *P<0.05, **P<0.005, ***P<0.001 
(unpaired Student’s t-test) 21. 
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Of note, lack of CCR2 or MCP-1 inhibition by mNOX-E36 also affected the 
subpopulations of circulating blood monocytes, because Gr1hi monocytes were 
reduced in comparison to their Gr1lo-expressing counterparts. Collectively, these 
data demonstrated that the hepatic accumulation of macrophages upon chronic 
liver injury can be effectively attenuated by mNOX-E36 in vivo. 
 
Fig. 11 Effects of 
mNOX-E36 on non-
macrophage hepatic 
leukocyte infiltration 
upon chronic MCD 
diet-induced metabolic 
injury in vivo 
C57bl/6 WT mice 
were fed by a 
methionine choline 
deficient (MCD) diet 
for 8 weeks. 20mg/kg 
mNOX-E36 was 
administered s.c. 
three times per 
week. (A-E) Statistical analysis, based on FACS staining for intrahepatic 
leukocytes, revealed no significant alterations of hepatic non-macrophage 
immune cell subpopulations, specifically T-helper cells (CD4+, A), cytotoxic T 
cells (CD8+, B), NK cells (NK1.1+CD3-, C), NKT cells (NK1.1+CD4+, D) or B cells 
(CD19+, E). (F) Flow cytometric analysis of blood monocytes 
(CD115+CD11b+Ly6G- cells) for the distribution of the two major monocyte 
subsets (i.e. Gr1hi and Gr1low expressing monocytes) showed a reduced fraction 
of Gr1hi expressing inflammatory monocytes in mNOX-E36 injected and in CCR2-
/- mice. All data are expressed as the mean ± SD from three independent 
experiments, comprising n=10-12 for animals in the treatment and n=5-7 animals 
in the control groups. *P<0.05, **P<0.005, ***P<0.001 (unpaired Student’s t-test) 
21. 
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7.3.2. Reduction of liver infiltrating macrophages via mNOX-E36 
affects intrahepatic proinflammatory cytokines upon injury 
I next investigated the consequences of blocking hepatic macrophage 
accumulation via mNOX-E36 in the liver. An important function of hepatic 
macrophages during disease progression is the secretion of pro-inflammatory 
cytokines. Therefore, cytokines were measured from total liver protein lysates by 
ELISA. Mice that were kept on MCD diet displayed elevated levels of pro-
inflammatory cytokines like TNFα, IL-6 and MCP-1 in comparison to control diet. 
Animals that received long-term mNOX-E36 treatment had lower intrahepatic 
concentrations of TNFα, IL-6 and IFNγ (Fig. 12), in line with the reduced numbers 
of intrahepatic macrophages. Gene expression analysis by qPCR confirmed 
these data (not shown). Of note, mNOX-E36 treated animals showed much 
higher levels of MCP-1 in the liver, alongside a strongly induced MCP-1 gene 
expression. This is expected, because MCP-1 that is functionally antagonized by 
mNOX-E36 is still detected by the ELISA 120. Altogether, the clear reduction of 
pro-inflammatory cytokines in livers of mNOX-E36 treated animals indicated that 
pharmacological inhibition of MCP-1 might be capable of limiting chronic liver 
injury in vivo. 
Fig. 12 mNOX-E36 administration 
affects intrahepatic proinflammatory 
cytokines upon injury 
C57bl/6 WT mice were fed by a 
methionine choline deficient 
(MCD) diet for 8 weeks. 20mg/kg 
mNOX-E36 was administered s.c. 
three times per week. Cytokines 
were measured from total l iver 
protein extracts by ELISA. All data 
are expressed as the mean ± SD 
from three independent 
experiments, comprising n=10-12 
for animals in the treatment and 
n=5-7 animals in the control 
groups. *P<0.05, **P<0.005, 
***P<0.001 (unpaired Student’s t-
test) 21. 
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7.3.3. Steatosis development, but not fibrosis progression is 
attenuated in mNOX-E36 treated mice 
It has been shown before that CCR2-/- mice develop significantly reduced liver 
fibrosis upon CCl4 damage, because infiltrating macrophages were found to 
release distinct pro-inflammatory cytokines and directly activate collagen-
producing stellate cells 26,103,104. I thus assessed liver fibrosis progression in both 
models by quantifying collagen deposition in Sirius-Red staining as well as 
measuring the hepatic hydroxyproline content, an amino acid that is abundantly 
found in collagen fibers (Fig. 13). While CCR2-/- mice showed an attenuated 
development of liver fibrosis in the chronic CCl4 model and after MCD diet, as 
anticipated from prior studies 26,103,104, treatment with mNOX-E36 did not 
significantly affect hepatic fibrogenesis in both experimental models. 
I next analysed whether pharmacological inhibition of MCP-1 might represent a 
successful therapeutic approach to limit disease progression in chronic liver 
injury models. Several recent observations have linked the progression of 
steatohepatitis to the stimulation of TNF-dependent signaling pathways in 
hepatocytes upon injury. Thus, I hypothesized that the reduction of intrahepatic 
macrophages and its associated proinflammatory cytokines might reduce the 
development of steatosis in vivo. Indeed, fatty degeneration of the liver was 
attenuated in mice fed MCD diet when mNOX-E36 was administered, as 
evidenced by reduced steatosis by Oil red O staining as well as histopathological 
criteria scored by a blinded and experienced pathologist (Fig. 14). Subsequently, 
hepatic triglyceride content was significantly decreased in mNOX-E36 treated 
animals in the MCD diet model. Similar findings were obtained in CCl4–treated 
mice as well, although steatosis was much less prominent in this toxic model 
compared to MCD diet. 
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Fig. 13 mNOX-E36 administration does not significantly alter hepatic fibrosis 
progression in two independent experimental models 
C57bl/6 WT mice were subjected to 6 weeks of CCl4 injury (A-C) or to 8 weeks of 
MCD diet (D-F) and treated long-term with mNOX-E36 as described in the main 
text. Collagen deposition in the l iver was visualized by Sirius Red staining (A, 
D), showing bridging fibrosis after CCl4 administration (A) and scattered collagen 
in steatotic l ivers after MCD diet (D). Histological collagen deposition was 
quantif ied in a blinded, computer-based fashion (B, E). Hydroxyproline content of 
the l ivers was quantif ied as an additional measure of total hepatic collagen (C, 
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F). Collectively, the data demonstrated attenuated fibrosis development in 
CCR2-/- mice, but no significant effect of mNOX-E36. All data are expressed as 
the mean ± SD from three independent experiments, comprising n=10-13 for 
animals in the treatment and n=5-7 animals in the control groups. *P<0.05, 
**P<0.005, ***P<0.001 (unpaired Student’s t-test) 21. 
 
In line with the attenuated steatosis development, expression of the protective 
transcription factor PPARg (peroxisome proliferator-activated receptor g) was 
induced, whereas PEPCK (phosphoenolpyruvate carboxykinase), an important 
driver of hepatic gluconeogenesis, was reduced in mNOX-E36-treated animals in 
the MCD diet model. Thus, our results demonstrated that steatosis progression is 
closely associated with MCP-1-dependent macrophage recruitment and 
subsequent inflammation. 
 
 
See over for figure legend 
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Fig. 14 mNOX-E36 protects from steatosis development in experimental liver injury 
C57bl/6 WT mice were fed by a methionine choline deficient (MCD) diet for 8 
weeks. 20mg/kg mNOX-E36 was administered s.c. three times per week. (A) Oil 
red O staining of l iver cryosections showed decreased levels of positive stained 
intracellular fat vacuoles in mNOX-E36 treated mice. (B) Pathological scoring of 
l iver histology by a blinded pathologist shows attenuated fatty degeneration in 
mNOX-E36 injected mice. (C) Quantif ication of tr iglycerides from total l iver 
lysates revealed reduced triglyceride content in murine l iver after mNOX-E36 
treatment. (D, E) Gene expression analysis from whole l iver by quantitative real-
t ime PCR showed induced hepatic peroxisome proliferator-activated receptor 
gamma (PPARg) and reduced phosphoenolpyruvate carboxykinase (PEPCK) 
mRNA levels in mNOX-E36- injected mice.All data are expressed as the mean ± 
SD from three independent experiments, comprising n=10-12 for animals in the 
treatment and n=5-7 animals in the control groups. *P<0.05, **P<0.005, 
***P<0.001 (unpaired Student’s t-test) 21. 
 
 
7.4. mNOX-E36 also ameliorates steatosis development upon 
therapeutic application 
In order to test the therapeutic potential of mNOX-E36 to treat ongoing fatty liver 
degeneration, mice were kept on an MCD diet for 6 weeks without treatment, 
which induced severe steatohepatitis (not shown). While the MCD diet was 
continued, mNOX-E36 was administered during the last 2 weeks of injury. 
Clearly, mNOX-E36 treatment in this therapeutic setting reduced hepatic 
steatosis, as intrahepatic lipid vacuoles and the histological fatty degeneration 
score improved upon MCP-1 inhibition. Moreover, the hepatic triglyceride content 
showed a trend towards lower levels in the mNOX-36-treated animals . These 
data indicated that inhibition of MCP-1 might be a promising therapeutic strategy 
even in ongoing or established steatohepatitis (Fig. 15). 
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Fig. 15 mNOX-E36 ameliorates 
hepatic steatosis in a therapeutic 
setting 
C57bl/6 wild-type (WT) mice were 
fed a methionineecholine- deficient 
(MCD) diet for 8 weeks. mNOX-E36 
at 20 mg/kg was administered 
subcutaneously three times per 
week only during the last 2 weeks 
of the diet. (A) Conventional H&E 
staining of l iver paraffin sections 
showed fatty degeneration after 
feeding the MCD diet. Treatment 
with mNOX-E36 resulted in lower amounts of cells with large fat vacuoles. (B) 
Pathological scoring of l iver histology by a blinded pathologist showed 
attenuated fatty degeneration in mNOX-E36-injected mice. (C) Quantif ication of 
tr iglycerides from total l iver lysates revealed a trend of reduced triglyceride 
content in murine l iver after mNOX-E36 treatment. All data are expressed as the 
mean6SD with n1⁄44 animals per group. *p<0.05 (unpaired Student t test) 21. 
 
7.5. Regression of liver fibrosis after chronic injury 
7.5.1. Dynamic changes of infiltrating macrophage subsets during 
regression of chronic toxic liver fibrosis 
Macrophage infiltration into the liver upon chronic injury has been convincingly 
linked to the progression of liver inflammation and fibrosis 6,26,102,121. More 
recently, so-called ‘restorative macrophages’ have been identified that are 
believed to functionally contribute to the regression of liver fibrosis, likely via 
degrading matrix proteins by distinct metalloproteinases (MMPs). When mice 
were challenged with CCl4 i.p. (0.6 ml/kg body weight) twice per week for six 
weeks to induce liver fibrosis, severe damage with necrotic patches in histology, 
mononuclear infiltrates and fibrotic bridging as well as increased 
aminotransferase activity levels in serum were evident at 48h after the last of 
repetitive CCl4 injections. At this time-point, representing the peak of injury and 
fibrosis in the chronic toxic model 26, a massive infiltration of leukocytes, 
especially macrophages, was detectable by immunohistological staining for the 
leukocyte marker CD45 and the macrophage marker F4/80. As soon as mice 
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were allowed to recover from chronic toxic injury, transaminase levels rapidly 
decreased to normal values within 5 and 7 days after the last CCl4 injection, while 
inflammatory infiltrates and fibrosis appeared to decline at a slower rate (Fig. 16). 
 
See over for figure legend 
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Fig. 16 Dynamic changes of intrahepatic macrophage subsets during regression from 
chronic toxic liver damage 
C57bl/6 wildtype (WT) mice were i.p. injected with carbon tetrachloride (CCl4) 
twice weekly for 6 weeks and analysed during regression at the indicated time-
points. (A) Liver histology of paraffin sections showed necrosis and progressive 
mononuclear infi l trates in the periportal regions of chronic injured l ivers from WT 
mice (Hematoxylin-eosin stainings, HE), collagen deposition (sirius red 
stainings), leukocyte and macrophage infi l tration (identif ied by 
immunohistochemistry for CD45 and F4/80, respectively). (B) Hepatic injury was 
also assessed by serum aspartate (AST) and alanine aminotransferase (ALT) 
levels. (C) Infi ltration of leukocytes (percentage of CD45+ cells from total l iver 
cells) and infi l trating macrophages (iMΦ ; Hoechst-dye-/CD45+/Ly-6G-
/CD11b+/F4/80+) into the l iver was quantif ied by FACS, revealing decreasing 
numbers of iMΦ  during regression. (D-E) FACS analyses of intrahepatic iMΦ  
subsets (pregated as described) showing elevated numbers of Ly-6C+ and 
reduced numbers of Ly-6C- intrahepatic macrophages after 7d of regression. All 
data are expressed as mean±SD, comprising n=9 animals in each group. 
*p<0.05, **p<0.005, ***p<0.001, ****p<0.0001 (unpaired Student’s t test)29. 
 
Recent studies had suggested a predominance of so-called ‘restorative 
macrophages’ during fibrosis regression, which was characterized by low to 
absent expression for the myeloid marker Ly-6C 117. In order to characterize the 
kinetics of intrahepatic macrophages in our model and to address their 
therapeutic targeting via inhibition of the chemokine CCL2, liver leukocytes were 
isolated and subjected to multi-color FACS analysis. Intrahepatic infiltrating 
macrophages (iMΦ) were defined as living (Hoechst-dye negative) CD45+ cells 
that stain positive for the myeloid marker CD11b, intermediate for the 
macrophage marker F4/80 and negative for the neutrophil marker Ly-6G 21 and 
were divided in Ly-6C+ and Ly-6C- expressing subpopulations. During fibrosis 
regression, the total number of hepatic leukocytes declined, mostly due to 
decreasing numbers of iMΦ. Strikingly, the relative composition of iMΦ changed 
significantly during regression, with a progressive increase of the Ly-6C+ iMΦ 
subset over 7 days, mirrored by decrease in the Ly-6C- population (Fig. 16), 
resulting in a similar Ly-6C+ to Ly-6C- ratio as in non-fibrotic livers of control mice. 
To further characterize these subsets of iMΦ during chronic liver damage, I 
isolated Ly-6C+ and Ly-6C- CD11b+F4/80+ hepatic macrophages by FACS 
sorting. Whereas the Ly-6C- population represented round-shaped “monocyte-
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like” cells with small cytoplasm and only few granules, the Ly-6C+ iMΦ displayed 
the typical appearance of “classical” macrophages, including a large, slightly 
irregularly shaped cell body and scattered granules in the cytoplasm, in line with 
proinflammatory (secretory and phagocytic) activities (Fig. 17). These findings 
were corroborated by gene expression analysis of the subsets, because the Ly-
6C+ iMΦ expressed higher levels of TNF, especially in fibrotic livers, compared to 
the Ly6C- fraction or compared to CD11blowF4/80+ resident macrophages. 
Interestingly, expression of CCR2 was only slightly enhanced in Ly-6C+ iMΦ, 
contrasting the high CCR2 expression of the Ly-6Chigh blood monocytes, which 
are the circulating precursors of the Ly-6C+ iMΦ in inflamed liver. Collectively, 
these data indicated that Ly-6C+ iMΦ might represent a rather proinflammatory 
macrophage population during fibrosis regression (Fig. 17).  
 
Fig. 17 Morphology and phenotype of intrahepatic macrophage subsets during 
regression from chronic liver damage 
(A) C57bl/6 WT mice were fed by an MCD diet for 6 weeks to induce chronic 
steatohepatit is and analysed after 5 days of regression. Cytospins from sorted 
Ly-6C+ and Ly-6C- cells of iM revealed the morphology of metabolically active 
macrophages in the Ly-6C+ population and a more “monocyte-like” appearance 
in the Ly-6C- subset. (B and C) Gene expression analysis from sorted Ly-6C+, 
Ly-6C-, and resident intrahepatic macrophages (MΦ , CD11blow F4/80+) by qPCR 
showed elevated TNF-alpha levels in Ly-6C+ cells, especially in f ibrotic l ivers. All 
data are expressed as mean6SD, comprising n55 for animals in the treatment 
and n54 animals in the control groups. *P<0.05; **P<0.005; ***P<0.001; ****P < 
0.0001 (unpaired Student t test) 29. 
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7.5.2. Inhibition of CCL2 transiently blocks Ly-6C+ iMΦ during 
fibrosis regression after toxic liver injury 
Former studies using Ccr2-/- mice demonstrated that chemokine receptor CCR2 
and its ligand CCL2/MCP-1 promote the infiltration of inflammatory Ly-6C+ (Gr1+) 
monocytes into the liver 21,26,103,104. I had previously shown that the inhibition of 
CCL2/MCP-1 by the Spiegelmer mNOX-E36 efficiently blocks infiltration of Ly-
6C+ monocytes during fibrosis progression 21.  
 
 
See over for figure legend 
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Fig. 18 mNOX-E36 inhibits infiltration of Ly-6C+ iMΦ during fibrosis regression after 
toxic liver injury 
(A) C57bl/6 wildtype (WT) mice were i.p. injected with carbon tetrachloride 
(CCl4) twice weekly for 6 weeks and analysed during regression with or without 
additional s.c. admission of mNOX-E36 (or tracer [glucose 5%] control) at the 
indicated time-points. (B) Hepatic injury was assessed by serum alanine 
aminotransferase (ALT) levels. (C-D) Infi ltration of leukocytes (CD45+) and iMΦ  
(gated as described before) into the l iver was quantif ied by FACS, revealing 
decreased numbers of iMΦ  upon mNOX-E36 administration after 5d. (E-F) FACS 
analyses of intrahepatic iMΦ  subsets (Ly-6C+/-) from mice treated with mNOX-
E36 showing reduced numbers of Ly-6C+ and elevated numbers of Ly-6C- 
intrahepatic macrophages after 5d of regression. All data are expressed as 
mean±SD, comprising n=12 for animals in the treatment and n=5-7 animals in 
the control groups. *p<0.05, **p<0.005, ***p<0.001, ****p<0.0001 (unpaired 
Student’s t test) 29. 
 
To investigate the functional role of iMΦ subsets during fibrosis regression, I 
injected mNOX-E36 (20 mg/kg) s.c. daily, starting at 24h after the last of 
repetitive CCl4 injections. While the rapid decline of serum ALT levels and the 
overall numbers of intrahepatic leukocytes were not affected by mNOX-E36, 
FACS analyses of intrahepatic leukocytes revealed a significant reduction of iMΦ 
upon mNOX-E36 administration at 5 days of regression, indicating an continuous 
and CCL2-dependent influx of (blood-derived) monocytes into regenerating liver 
during fibrosis regression. Subsequent phenotyping of the iMΦ disclosed a gain 
of the relative content of Ly-6C- macrophages, while Ly-6C+ iMΦ were reduced 
(Fig. 18). 
Interestingly, these effects of CCL2 inhibition on the composition of hepatic iMΦ 
was observed only at 5 days of regression, suggesting that CCL2 dependent 
recruitment of Ly-6C+ monocytes is a transient event relatively early during 
regression from liver fibrosis. Importantly, these effects were specific to hepatic 
macrophages, because other intrahepatic leukocyte subpopulations such as T- 
(CD8+, CD4+) or NK-cells were not affected by mNOX-E36 administration (Fig. 
19). 
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Fig. 19 Analysis of non-
macrophage intrahepatic immune 
cells during regression from toxic 
liver fibrosis 
C57bl/6 wildtype (WT) mice were 
i.p. injected with carbon 
tetrachloride (CCl4) twice weekly 
for 6 weeks and analysed during 
regression with or without 
additional s.c. admission of 
mNOX-E36 at the indicated time-
points. FACS analyses were 
conducted to assess intrahepatic 
numbers of T-cells (CD45+CD4+, CD45+CD8+, A), NK-cells (CD45+NK1.1+, B) and 
B-cells (CD45+CD19+, C). All data are expressed as mean±SD. *p<0.05, 
**p<0.005, ***p<0.001, ****p<0.0001 (unpaired Student’s t test for mouse data, 
respectively) 29. 
 
7.5.3. CCL2-dependent variations of iMΦ subsets during 
regression of chronic metabolic liver injury 
In order to exclude that model-specific effects had confounded the above-
mentioned results, I employed a second model of chronic liver injury. Mice were 
fed a methionine and choline-deficient (MCD) diet for 8 weeks, resulting in severe 
steatohepatitis at a macroscopic and microscopic level as well as elevated ALT 
and AST (not shown) levels 21. When mice were switched to a normal chow diet 
to induce regression from steatohepatitis, liver injury (histology, ALT) was 
significantly reduced after 5 days, alongside a significant reduction in total 
hepatic leukocytes and intrahepatic CD11b+F4/80+ iMΦ. Inhibition of CCL2/MCP-
1 by mNOX-E36 further reduced hepatic leukocyte and iMΦ counts during 
regression. Moreover, in line with the results from the CCl4 injury model, the 
composition of intrahepatic macrophages was altered by mNOX-E36, resulting in 
a reduced proportion of Ly-6C+ and increased proportion of Ly-6C- iMΦ (Fig. 20).  
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Fig. 20 mNOX-E36 inhibits infiltration of Ly-6C+ iMΦ during fibrosis regression after 
metabolic liver injury 
(A) C57bl/6 wildtype (WT) mice were fed by a methionine-choline deficient 
(MCD) diet for 8 weeks to induce steatohepatit is as well as fibrosis and analysed 
during regression with or without mNOX-E36 or tracer control treatment at the 
indicated time-points. (B) Liver histology of paraffin sections showed attenuated 
mononuclear infi l trates in the periportal regions of steatotic l ivers from mNOX-
E36 treated mice (Hematoxylin-eosin stainings) and attenuated macrophage 
infi ltration (identif ied by immunohistochemistry for F4/80 and FACS analysis). 
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(C) Hepatic injury was assessed by ALT levels. (D) Infi ltration of leukocytes 
(CD45+) and iMΦ  (gated as described before) into the l iver was quantif ied by 
counting of CD45+ cells on immunohistological stained l iver sections and FACS 
analyses, revealing decreased numbers of iMΦ  upon mNOX-E36 administration 
after 5d. (E-F) FACS analyses of intrahepatic iMΦ  subsets (Ly-6C+/-) from mice 
treated with mNOX-E36 showing reduced numbers of Ly-6C+ and elevated 
numbers of Ly-6C- intrahepatic macrophages upon mNOX-E36 treatment after 5d 
of regression. All data are expressed as mean±SD, comprising n=10-12 for 
animals in the regression and n=5-7 animals in the control groups. *p<0.05, 
**p<0.005, ***p<0.001, ****p<0.0001 (unpaired Student’s t test) 29. 
 
Again, other intrahepatic leukocyte populations were not affected by mNOX-E36 
administration during the regression phase in the MCD diet model (Fig. 21). 
Collectively, these data indicated Ly-6C+ monocytes transiently accumulate in the 
liver in both models of regression from chronic liver injury, which can be partially 
blocked by pharmacological inhibition of the chemokine CCL2/MCP-1. 
 
Fig. 21 Analysis of 
intrahepatic immune cells 
during regression from 
metabolic liver fibrosis 
C57bl/6 wildtype (WT) mice 
were fed a MCD diet for 8 
weeks and analysed during 
regression with or without 
additional s.c. admission of 
mNOX-E36 at the indicated 
time-point. (A-E) FACS 
analyses were conducted to 
assess intrahepatic numbers 
of total leukocytes (CD45+, 
A), Kupffer cells (KC, CD45+ 
Ly6G- CD11blow F4/80++, B), 
T-cells (CD45+ CD4+, 
CD45+CD8+, C), NK-cells (CD45+ NK1.1+, D) and B-cells (CD45+CD19+, E).  (F) 
Hepatic injury during regression from MCD diet induced liver f ibrosis was also 
assessed by AST levels. (G) Pathological scoring of fatty l iver degeneration by a 
blinded pathologist showed no difference after mNOX-E36 treatment. All data 
are expressed as mean±SD. *p<0.05, **p<0.005, ***p<0.001, ****p<0.0001 
(unpaired Student’s t test) 29. 
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7.5.4. Fibrosis regression is accelerated in mNOX-E36 treated 
mice after toxic and metabolic chronic liver injury 
I hypothesized that pharmacological inhibition of CCL2/MCP-1 could represent a 
successful therapeutic approach to enhance fibrosis regression in chronic liver 
injury in vivo by blocking Ly-6C+ monocyte infiltration and shifting the iMΦ 
population towards the Ly-6C- phenotype. Indeed, fibrotic degeneration of the 
liver was significantly attenuated in mice with chronic CCl4-induced toxic liver 
damage after 7 days of regression upon mNOX-E36 administration, as evidenced 
by reduced collagen deposition in histology, hydroxyproline content and sirius red 
positive areas. Similar findings were observed during recovery from metabolic 
MCD diet-induced liver injury. Here, also a significant reduction of the content of 
hydroxyproline and lower levels of sirius red positive areas were detected when 
CCL2 was inhibited by mNOX-E36 (Fig. 22). 
Hepatic triglyceride content as a measure for steatosis was not further decreased 
in mNOX-E36 treated animals in the MCD diet regression model, indicating 
specific effects of the iMΦ subsets in controlling fibrosis regression. In line with 
the histological and biochemical data on fibrosis regression, quantitative 
expression analyses of fibrosis-related genes confirmed reduction of α-SMA and 
collagen mRNA in liver samples of mice treated with mNOX-E36 during 
regression (Fig. 22). 
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Fig. 22 mNOX-E36 treated mice show accelerated regression from liver fibrosis induced 
by CCl4 or MCD diet 
Liver f ibrosis was induced in C57bl/6 wildtype (WT) mice, and mNOX-E36 was 
administered as described. (A) Collagen deposition, as quantif ied by intrahepatic 
hydroxyproline measurement and sirius red stainings, was significantly 
decreased in mNOX-E36 treated mice after 7d of regression from toxic l iver 
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f ibrosis. (B) Liver histology of paraffin sections showed attenuated CD45+ 
infi l trates in the periportal regions of steatotic l ivers from mNOX-E36 treated 
mice (immunohistochemistry for CD45) and reduced collagen deposition (sirius 
red stainings) during regression from MCD diet. (C) Collagen deposition, as 
quantif ied by intrahepatic hydroxyproline measurement and sirius red stainings, 
was significantly decreased in mNOX-E36 treated mice mice after 5d of 
regression from metabolic l iver f ibrosis. (D) Quantif ication of tr iglycerides from 
total l iver lysates revealed no different in murine l iver with or without mNOX-E36 
treatment. (E) Gene expression analyses from whole l iver by quantitative real-
t ime PCR showed reduced hepatic α-SMA and collagen mRNA levels in mNOX-
E36 injected mice. All data are expressed as mean±SD, comprising n=10-12 for 
animals in the treatment and n=5-7 animals in the control groups. *p<0.05, 
**p<0.005, ***p<0.001, ****p<0.0001 (unpaired Student’s t test) 29. 
 
 
7.5.5. Pharmacological inhibition of CCL2-dependent Ly-6C+ iMΦ 
reduces intrahepatic pro-inflammatory cytokines during 
fibrosis regression 
An important function of hepatic macrophages during disease progression and 
regression is the secretion of pro-inflammatory cytokines 21,24,121. In order to 
explore potential mechanisms how blocking of Ly-6C+ iMΦs by mNOX-E36 
accelerates fibrosis regression, intrahepatic cytokine levels were measured. 
During regression from CCl4-induced fibrosis, expression of TNF-α and IFNγ was 
significantly down-regulated in livers of mice that received mNOX-E36, both on a 
gene and protein level. Similar findings were confirmed during regression from 
the MCD diet injury by qPCR (Fig. 23) and ELISA (data not shown). 
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Fig. 23 Intrahepatic cytokine alterations upon mNOX-E36 administration in vivo and in 
vitro 
Liver f ibrosis was induced in C57bl/6 wildtype (WT) mice, and mNOX-E36 was 
admitted as described. (A-C) Gene and protein expression analysis from whole 
l iver by quantitative real-t ime PCR and ELISA from whole l iver lysates showed 
reduced hepatic TNF-α  and IFNγ  levels in mNOX-E36 injected mice in regression 
from CCl4- (A-B) and MCD diet-induced (C) fibrosis. (D) Gene expression 
analysis from FACS-sorted iMΦ  showed reduced TNF-α  mRNA levels in mNOX-
E36 injected mice at regression from metabolic f ibrosis. (E) Bone marrow 
derived macrophages (BMM) were isolated and cultured with or without mNOX-
E36, followed by stimulation with IL4 (M2 polarization) or IFNγ  (M1 polarization). 
(F) Gene expression analysis by quantitative real-t ime PCR for TNF-α  (M1 
effector cytokine) and arginase 1 (M2 marker). All data are expressed as 
mean±SD, comprising n=6-12 animals for intrahepatic gene analyses and 
cytokine measurements, n=4 for gene analysis of FACS sorted iMΦ , and n=3 for 
gene analyses from BMM. *p<0.05, **p<0.005, ***p<0.001, ****p<0.0001 
(unpaired Student’s t test) 29. 
 
To link the intrahepatic cytokine profile to distinct mononuclear cell populations in 
the liver, primary hepatic iMΦ were isolated from livers of mice by FACS cell 
sorting (populations as depicted in Fig. 23) 23. After mNOX-E36 treatment iMΦ 
showed decreased expression levels of TNF-α, while the IFNγ synthesis was 
unaffected (Fig. 23). Of note, TNF-α expression in simultaneously isolated 
Kupffer cells (F4/80++CD11blow) remained unaffected by mNOX-E36 treatment 
(data not shown).  
In order to exclude that the CCL2-inhibitor mNOX-E36 itself had direct or indirect 
(e.g., via interfering with autocrine CCL2 pathways) effects on TNF-α expression, 
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bone marrow-derived macrophages were generated from WT mice, cultured with 
or without presence of mNOX-E36 and stimulated with either IFNγ (M1 
polarization) or IL4 (M2 polarization). As depicted in Fig. 23, neither the baseline 
nor the IFNγ–induced TNF-α expression were suppressed by mNOX-E36. Of 
note, mNOX-E36 treatment on macrophages did not induce or facilitate IL4-
induced M2 polarization either, as assessed by Arginase-expression. Therefore, 
the reduced expression of TNF-α by iMΦ upon mNOX-E36 administration 
indicates that the infiltrating CCL2-dependent Ly-6C+ monocytes/macrophages 
exert pro-inflammatory actions 121, while Ly-6C- macrophages endorse liver 
fibrosis regression. 
Furthermore, I wanted to ensure that mNOX-E36 specifically inhibits Ly-6C+ 
monocyte migration from the circulation into the liver and exclude that the 
changes in intrahepatic macrophage subsets are a secondary effect of 
accelerated fibrosis regression induced by mNOX-E36 by alternative pathways. 
Therefore, Ly-6C+ monocytes were isolated from BM of RFP Tg mice and 
adoptively transferred into mice challenged with CCl4. Twentyfour hours after 
injury induction, a clear hepatic infiltration of RFP+ monocytes was revealed. This 
intrahepatic Ly-6C+ monocyte accumulation could be almost completely blocked 
(to background levels) by a single injection of mNOX-E36 (Fig. 24). Moreover, 
adoptively transferred RFP+ Ly-6C+ monocytes recovered from liver displayed 
similar Ly-6C expression levels as endogenous intrahepatic Ly-6C+ iMΦs, 
corroborating that mNOX-E36 did not simply induce a rapid down-regulation of 
Ly-6C expression  
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Fig. 24 Fig. 7. Infiltration of Ly-6C+ macrophages, but not macrophage polarization, is 
blocked by mNOX-E36 
(A) BMMs were isolated and cultured with or without mNOX-E36, followed by 
stimulation with IL-4 (M2 polarization) or IFN-c (M1 polarization). (B) Gene 
expression analysis by qPCR for TNF-a (M1 effector cytokine) and arginase 1 
(M2 marker). (C and D) Adoptive transfer of Ly-6C+ monocytes isolated from BM 
of RFP- expressing mice displayed infi l tration of RFP+Ly-6C+ monocytes 24 
hours after CCL4 injury, which could be effectively blocked by a single 
administration of mNOX-E36. All data are expressed as mean 6 SD, comprising 
n 5 12 for animals in the treatment and n 5 5-7 animals in the control groups. *P 
< 0.05; **P < 0.005; ***P < 0.001; ****P < 0.0001 (unpaired Student t test)29. 
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8. Discussion 
In humans chronic liver diseases are a complex challenge in modern medical 
care. Different chronic illnesses (e.g. viral hepatitis, alcoholism, obesity or 
diabetes) provide the same result through similar inflammatory pathways: 
parenchymal destruction with fibrotic conversion. In detail, a massive hepatocytic 
stress responses (e.g. apoptosis or steatosis) is triggered by chronic liver injury 
(i.e. chronic liver illnesses) and is accompanied by a prominent inflammatory 
response as well as wound-healing reactions by non-parenchymal cells 1. 
The hepatic inflammation is a highly regulated process, and the increased 
expressions of distinct CC- and CXC- chemokines and their receptors have been 
identified as major regulators of immune cell recruitment into the injured liver. For 
example, in patients with chronic liver diseases CXCR6 and CXCL16 expression 
was intrahepatically upregulated compared with controls. Recently Wehr et al. 
showed in murine models that the chemokine receptor CXCR6 and its ligand 
CXCL16 controls NKT cell migration into the liver and so controls functional 
mechanisms in liver fibrosis 14. Here, NKT cells interact intrahepatically with both: 
resident as well as infiltrating hepatic macrophages, which are the key players in 
developing inflammatory triggered hepatic fibrosis. Convincing evidence exists 
that the CCR2/MCP-1 axis fulfils a central role in communication with other 
immune cells like NKT cells and macrophage-mediated liver inflammation 4,36. In 
murine models the CCR2/MCP-1 axis in monocyte/macrophage recruitment 
during experimental hepatic inflammation is therefore a central area of research 
of the chronic injured liver. Several independent experimental studies underlined 
the position of the chemokine receptor CCR2 in hepatic inflammation and its 
main ligand monocyte-chemoattractant protein 1 (MCP-1/CCL2) 10,103,104,123, 
suggesting that inhibition of the CCR2/MCP-1 axis might allow therapeutic benefit 
chronic liver diseases. In this study, I demonstrate that specific blocking of the 
CCR2/MCP-1 axis by the MCP-1 antagonist mNOX-E36 effectively inhibits 
intrahepatic macrophage accumulation and prevents steatosis development. I 
was able to validate this effect of MCP-1 antagonism in different liver injury 
models: upon toxic (CCl4-injections) and metabolic liver damage (MCD-diet). 
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The migration of monocytes/macrophages by CCR2 is not a liver specific 
phenomenon. CCR2 rather mediates the directed infiltration of 
monocytes/macrophages to areas of injury and inflammation in many organs 
during different diseases 13. First of all CCR2-mediated actions are central for 
migration of monocytes between the bone marrow and the blood 12,26,124, but also 
in a second step from the bloodstream into inflamed tissues like the kidneys and 
brain 12,125. Within the CCR2/MCP-1 axis blocking MCP-1, the main ligand for 
CCR2, appears thus as an appealing therapeutic approach in many 
inflammatory-triggered illnesses. For example it was shown that pharmacological 
antagonism of CCR2 or MCP-1 is capable of blocking macrophage infiltration into 
adipose tissue and improving insulin sensitivity in experimental models of obesity 
123,126,127. Furthermore, in murine livers CCR2-deficient mice (CCCR2-/-) showed 
a significant phenotype towards a less inflamed and fibrotic organ during liver 
injury models 26. 
In my studies I used a new approach in blocking a specific cytokine without 
operating with an antibody. The so called ‘Spiegelmer’ mNOX-E36, which is 
highly specific for the chemokine MCP-1, is a very attractive pharmacological 
approach, because it has favourable pharmacokinetic characteristics (suggesting 
efficient plasma levels at a once or twice weekly dosing schedule): it is highly 
effective at nanomolar concentrations and has no significant immunogenic 
activity in vivo 110,111,120.  
My study now validated that the Spiegelmer mNOX-E36 was not only sufficient to 
inhibit monocyte (isolated from the bone marrow) migration in vitro, but also 
effectively and specifically reduced the accumulation of intrahepatic 
macrophages upon acute or chronic liver injury in vivo. To exclude an experiment 
specific bias I established different models of liver damage following human 
examples of chronic liver injury. Here, the effects of reduced intrahepatic 
macrophage accumulation were independent of the underlying cause of liver 
damage: I showed similar rates of hepatic macrophage reduction in chronic toxic 
(CCL4-injections) and metabolic injury models (MCD-diet). 
One and the same macrophage can exert different functional actions within the 
liver. For instance, the initialization, perpetuation or resolution of hepatic 
inflammation is exerted by macrophages dependent on their immunological 
activation or differentiation (so called M1- vs M2-type differentiated 
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macrophages). The different immunological activation of the macrophage on the 
other hand is influenced by the local hepatic microenvironment and age of the 
macrophage 9,101,107,121. 
In this study, I was focussed on chronic liver disease models leading in organ 
fibrosis. I was able to show that during disease progression, mNOX-E36 
administration significantly reduced the protein levels of hepatic proinflammatory 
cytokines (TNFα, IL-6), in line with reduced numbers of macrophage. The 
detected cytokine profile as well as specific surface markers (FACS analysis) 
suggested that mNOX-E36 predominantly affected ‘classical’ M1-type 
differentiated macrophages. However, I cannot exclude that different 
macrophage subsets may be changed during regression or resolution of liver 
injury 104. 
In a second step I was focused on the parenchymal changings during organ 
injury. Overall, administration of mNOX-E36 improved hepatic steatosis, but not 
ameliorated fibrosis in two independent chronic injury models (CCl4-injections 
and MCD-diet). Interestingly, similar data have been acquired with distinct knock-
out (MCP-1-/-) mice. While CCR2-/- mice were protected from fibrosis 
development in several independent studies 26,103,104, this was not repeatable in 
MCP-1-deficient animals105. Given the clear relationship between macrophages 
and fibrosis progression 6,9,107,121, several factors may explain this observation. 
First, my murine models (especially in ‘slow-fibrosing’ c57bl/6 mice) investigated 
a rather early stage of fibrosis progression; possibly, long-term effects on fibrosis 
may have been unseen in this experimental setting and may be apparent at more 
progressed disease. Second, the reduction of macrophages achieved by mNOX-
E36 at the used dose may not be suitable to suppress levels below a certain 
threshold, suggesting that higher doses should be evaluated in future studies 120. 
Furthermore, it is thinkable that mNOX-E36 should be combined with additional 
antagonists for alternative CCR2 ligands such as MCP-3 (CCL7) 28,103. Third, 
blocking MCP-1 may sufficiently suppress infiltration of monocytes or 
macrophages into the liver, but not of other CCR2-expressing immune cells (e.g. 
B-cells), which also ameliorates organ fibrosis. Of note, a recent study identified 
hematopoietic and progenitor cells that traffic into injured liver via CCR2 102, 
which would be consistent with my finding that CCR2-/- mice differ substantially 
from the mNOX-E36 treated animals with respect to fibrosis development. Forth, 
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the Spiegelmer mNOX-E36 primarily stopped typical M1-type macrophage 
functions such as TNF production; however, several lines of evidence indicate 
that alternatively activated macrophages (M2) may specifically exert 
profibrogenic actions, like TGFβ synthesis or stellate cell activation 107. From 
there it is also thinkable that blocking M1-type macrophages changes the ratio 
between the different activated macrophages in favour of M2-type macrophages. 
Nevertheless I was able to show that the treatment with mNOX-E36 significantly 
improved the development of hepatic steatosis upon chronic metabolic injury 
caused by a MCD-diet. Hepatic fat accumulation is manly caused by elevated 
lipogenesis through stimulating lipogenic enzymes via the transcription factor 
SREB-1c 99. This lipogenic cascade can be activated by different stimuli: e.g. 
hyperinsulinemia or inflammatory cytokines 128. My observation, that a hepatic 
steatosis progression is reduced by mNOX-E36 administration is in well 
agreement with results from other groups with MCP-1 deficient mice or groups, 
which blocked the receptor CCR2 by the inhibitor propagermanium. Here it was 
possible to show that MCP-1 deficient mice, which were fed a high-fat diet, also 
ameliorated hepatic steatosis and triglyceride content 123,127. Same results were 
shown in models, where the receptor CCR2 was blocked by the organometallic 
compound propagermanium. In both studies, pro-inflammatory cytokines 
released by macrophages in the liver but also in other compartments like adipose 
tissue were identified as crucial inductors of hepatic steatosis 123,127. Interestingly, 
the human equivalent of the MCP-1 inhibitor mNOX-E36 is currently being 
evaluated in clinical trials for the treatment of diabetic nephropathy. This 
highlights the clinical relevance the MCP-1 / CCR2 axis. Diabetic patients with 
metabolic syndrome almost always coincidentally present hepatic steatosis and 
have a highly increased risk of developing NASH. My study suggests that 
treatment with mNOX-E36 might bear additional advantages for diabetic patients 
by mediating anti-steatotic and anti-inflammatory actions in the liver.  
In humans, the only available curative treatment for end-stage liver disease is the 
transplantation of the liver. Therefore, there is an urgent need to find new 
therapeutic strategies for liver cirrhosis. Based on a growing knowledge of 
experimental evidence on the central function of monocytes/macrophages for 
fibrosis modulation, these cells might represent attractive novel targets for anti-
fibrotic strategies 17. Based on these findings prior studies investigated the 
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potential role of so called bone marrow (BM) cell therapy in liver fibrosis 6,129. 
Here the investigators used activated as well as partly inactivated (via specific 
cytokines) BM cells to influence intrahepatic / pro-fibrotic mechanisms, which 
were initially primed by inflammatory cells like macrophages. In detail, especially 
unstimulated bone marrow derived macrophages (BMM), which neither possess 
the typical classical (M1) nor the alternatively activated (M2) gene profile, 
achieved good results in preventing experimental liver fibrosis in mice. However, 
the effects were rather limited and the procedure is complex and not suitable for 
clinical use 6,130. It has also been shown that the administration of distinct 
macrophage subsets, especially subpopulations with low Ly-6C (Gr1) expression, 
can improve liver fibrosis during regression 26. On the other hand, adoptive 
transfer of immature Ly-6C+ bone marrow-derived monocytes aggravates 
experimental liver fibrosis 6,103. 
Anyway, transferring distinct cellular components of myeloid cells influences the 
balance between ‘inflammatory’ and ‘restorative’ macrophages within the liver. 
Such specific modulation between subsets of immune cells might bear 
therapeutic potential. In this study, I demonstrate that a novel antibody-similar 
compound for specific MCP-1 inhibition, the Spiegelmer mNOX-E36, effectively 
inhibits intrahepatic accumulation of Ly-6C+ iMΦ during regression from different 
chronic liver injury models (CCL4-injections as well as MCD-diet). Hereby, 
mNOX-E36 increased the proportion of restorative Ly-6C- macrophages within 
the liver, which finally led to accelerated regression from liver fibrosis after toxic 
or metabolic liver injury.  
As mentioned above, several independent studies highlighted the importance of 
the chemokine receptor CCR2 and its main ligand CCL2/MCP-1 for 
monocyte/macrophage recruitment during experimental hepatic fibrosis 
21,25,26,103,104, suggesting that inhibition of CCR2 or MCP-1 might bear therapeutic 
potential in chronic liver diseases, which lead to significant organ fibrosis. 
Nevertheless, inhibiting MCP-1 (CCL2) during fibrosis progression via the 
Spiegelmer mNOX-E36 efficiently ameliorated steatohepatitis in a murine model 
of metabolic liver damage. However, on the other side mNOX-E36 did not 
improve fibrosis development to a relevant extent 21. In contrary, my data clearly 
demonstrate that MCP-1 inhibition was efficient in accelerating regression from 
hepatic fibrosis in two independent experimental models. My findings thus 
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highlight the specific relevance of the (chemokine-dependent) accumulation and 
differentiation of monocyte/macrophage subpopulations during the regression of 
liver fibrosis. 
The positive actions of Ly-6C- ‘restorative’ macrophages within the liver have 
been confirmed for CCl4-induced fibrosis in studies before 117. This subset of 
‘restorative’ macrophages were linked to expression of matrix 
metalloproteinases, growth factors, and phagocytosis-related genes 112. 
However, it has been suggested that these ‘restorative’ macrophages mainly 
originate from Ly-6C+ monocytes, which freshly infiltrate the liver during 
regression of organ-fibrosis 112. The fact that inhibition of MCP-1 (CCL2) - 
dependent accumulation of Ly-6C+ monocytes within the liver during regressing 
from hepatic fibrosis effectively accelerates fibrosis regression indicates that 
these cells might rather act as a double-edged sword in fibrosis regression. 
Although Ly-6C+ monocytes might be capable of giving rise to restorative Ly-6C- 
macrophages, their inhibition results in a relative increase of either already 
existing Ly-6C- macrophages in the liver or recruitment of such cells from other 
precursors, e.g. from Ly-6C- monocytes 131 131. Importantly, my in-vitro 
experiments with bone marrow macrophages could exclude that the CCL2-
inhibitor itself had a direct impact on cytokine release from these macrophages or 
their M1/M2 polarization. From a functional point of view, mNOX-E36 
administration significantly reduced the levels of pro-inflammatory cytokines 
(TNF-α, IFNγ) during disease regression in the liver, in line with the reduced 
macrophage numbers. These results clearly assign the Ly-6C+ iMΦ a ‘pro-
inflammatory’ profile 107. My data indicate that perpetuation of inflammation, as 
reflected by pro-inflammatory cytokine levels in the liver, counteracts 
regenerative processes and degradation of extracellular matrix, thus inhibiting 
resolution of fibrosis 132. 
 Murine and human monocyte/macrophage subpopulations do not share 
the same surface marker molecules; this is the reason why it is not feasible to 
translate the findings from murine models into human pathogenesis 133. For 
instance, murine monocytes/macrophages are distinguished by different levels of 
Ly-6C (Gr1), while CD14 and CD16 are typical markers for corresponding 
subsets in humans 134. In fact, the exact human counterpart of ‘restorative 
macrophages’ (Ly-6C- in mice) still remains to be clarified. But the pro-
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inflammatory expression pattern of Ly-6C+ monocytes/macrophages observed 
during the regression phase of fibrosis is very similar to the phenotype of 
CD14++CD16+ ‘intermediate’ monocytes in human liver diseases 102,115. This is 
giving rise to the expectation that application of an MCP-1 inhibitor in human 
fibrosis regression holds significant therapeutic potential.  
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